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Chapter 1 - ABSTRACT
Loss of mismatch repair (MMR) and, in particular, loss of MLH1 is associated with
acquired cisplatin resistance of ovarian tumour cell line models. The aim of this
thesis is to examine in ovarian cancer patients the clinical prognostic significance of
the MMR proteins MLH1 and MSH2 when measured at disease presentation. We
have developed immunohistochemistry (IHC) and a scoring system for the expression
ofMLH1 and MSH2 in paraffin embedded tissues. We have scored both the intensity
of staining (I-score) and percentage of cells staining (%-score). We have validated
this technique with good agreement in scoring over time, between blocks and between
observers (inter-observer kappa scores of > 0.629, intra-observer kappa scores of
> 0.646 and intra-slide kappa scores of > 0.583). There was a positive correlation of
Ki67, (a proliferation marker), with I-MLH1, %-MLHl and %-MSH2 scores
(p=0.002; <0.001 and 0.001) but not with p53 scores.
We examined prechemotherapy samples from 58 patients with a histological
diagnosis of advanced ovarian carcinoma, who were then treated with primary
chemotherapy regimens containing cisplatin. Advanced stage was associated with
increased percentage cells positive for MLH1, MSH2 and Ki67 (p = 0.0092, 0.0049
and 0.0054 respectively). We performed a multivariate analysis allowing for known
clinical prognostic factors, (i.e. type of chemotherapy given, stage, performance status
and residual disease). Patients with a loss of intensity of staining for MMR proteins
prechemotherapy showed a poor survival (Hazard Ratio, HR=3.64; p=0.0012) and
poor progression free survival (HR=2.37; p=0.016). Similarly patients showing a
reduced intensity of MLH1 staining showed a poor overall survival (HR=2.17;
p=0.031). There was no correlation of MMR proteins and tumour response to
treatment.
Loss of mismatch repair (MMR) in ovarian tumour cells after cisplatin-based
chemotherapy has been shown in both in vitro and in vivo. We have examined paired
samples pre and post chemotherapy in 26 ovarian cancer patients. We have seen no
consistent changes in MMR proteins, p53 or Ki67 pre and post chemotherapy. On
multivariate analysis change in MMR expression did not correlate with survival but it
was found that a reduction in intensity of MSH2 staining post chemotherapy was
associated with a longer progression free survival (HR 0.52; p=0.011).
Although further prospective validation studies will be necessary, our observations
support the proposal that low MLH1 and/or MSH2 expression is associated with
resistance in vivo of ovarian tumours to cisplatin and hence poor survival of patients
after cisplatin-based chemotherapy.
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Chapter 2 - AIMS OF STUDY
I. To develop reliable immunohistochemistry for mismatch repair proteins in




D. Range of expression of proteins
E. Correlation with p53 and Ki67 expression
F. Expression in differentiated tissue (endometrial model)
II. To correlate expression ofmismatch repair proteins by immunohistochemistry
to the following:
A. Response to cisplatin based chemotherapy
B. Progression free survival
C. Overall survival
D. Clinical prognostic factors
III. To examine sequential ovarian tumour samples taken from the same patient
before and after chemotherapy for expression of mismatch repair proteins by
immunohistochemistry.
A. Overall differences
B. Correlation with clinical outcome
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Chapter 3 - INTRODUCTION
3 (i) DNA MISMATCH REPAIR
A - GENERAL INTRODUCTION
A (I) DNA repair in humans (eukaryotes)
DNA repair systems act to maintain genomic integrity in the face of replication errors,
environmental insults, and the cumulative effects of age. DNA repair can be defined
in a general sense as a range of cellular responses associated with the restoration of
the genetic instructions provided by the normal primary DNA sequence. More than
70 human genes directly involved in the five major pathways of DNA repair have
been described (Yu, Chen et al. 1999). The five pathways are not mutually exclusive
but are described briefly below.
1. Direct Repair. The simplest response to DNA damage is to remove or reverse
the lesion in a single step reaction, restoring the local sequence to its original state.
Human enzymes involved include 6-4 photolyase and 06-methyl-guanine DNA
methyltransferase (MGMT). MGMT is known to be important in repair of
alkylation damage.
2. Base Excision Repair (BER). This targets 'nonbulky' base adducts such as those
produced by methylation, oxidation, reduction, or fragmentation of bases by
ionizing radiation or oxidative damage. The removal of the modified base by a
DNA glycosylase is the major feature of BER. A pair of apurinic endonucleases
then incises the 3' and 5' next to the apurinic site. DNA polymerase p fills in the
gap and DNA ligase seals the nick. There are 5 characterised human DNA
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glycosylases with different but occasionally overlapping substrate specificity.
DNA ligases are a common pathway to BER and NER.
3. Nucleotide Excision Repair (NER). NER repairs bulky DNA adducts including
thymine dimers and 6-4 photoproducts. The major enzyme involved,
excinuclease, is a complex of at least 16 polypepetides. NER involves four stages;
damage recognition, incision, gap-filling and ligation.
4. Double strand break repair. Double strand breaks (DSB) arise in DNA under
physiological conditions e.g. somatic recombination, but are also produced by
ionizing radiation and oxidative insults. Mammalian cells primarily rejoin DSBs
by nonhomologous mechanisms but homologous repair is also found.
Homologous DSB repair involves physical interactions of RAD51, RAD52 and
RPA. Nonhomologous end-joining pathways of DSB repair begin with binding of
the free ends by DNA dependent protein kinase (DNA-PK). After binding of
subunits XRCC7, XRCC5 and XRCC6, DNA-PK is activated for its
phosphorylation activity involving XRCC4 and DNA ligase IV.
5. Mismatch Repair (MMR). Mismatched base pairs arise through processes
including misincorporations during DNA replication, formation of heteroduplexes
and secondary structures such as imperfect palindromes. Mismatches can also be
the results of deamination of 5-methylcytosine to thymidine resulting in a G:T
mismatch. In MMR a patch of nucleotides is removed from one strand, followed
by repair synthesis and ligation. This type of repair is the focus of this thesis and
shall now be discussed in more detail.
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A (II) DNA mismatch repair (MMR)
The most extensively characterised general mismatch repair system is the Escherichia
coli MutHLS system, which repairs a broad spectrum of mispaired bases and has been
reconstituted with purified enzymes. Eukaryotes are known to contain a MMR
system that contains at least some components that are highly related to key
components of the bacterial system, shown in table 1.
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Mut-S MSH6 Forms a heterodimer
with hMSH2.
The standard hypothesis of the mechanism of action of MMR presents a 'looping
model' in which MSH proteins form a complex with MLH proteins to bind
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mismatched nucleotides, thus creating a machine that translocates bi-directionally
from the mismatch to an 'activation'site. In E.coli this would be the MutH protein
bound to transiently hemi-methylated GATC sites in newly replicated DNA
(Kolodner 1996). Activation ofMutH results in single strand scission and loading of
the excision repair machinery, which leads to replacement of the error-containing
DNA strand. This model is confounded by the lack of MutH homologs or a
methylation requirement for MMR in humans.
A different model has been suggested by Fischel's group in which MSH proteins
function as an adenosine nucleotide regulated molecular switch (Fischel, Acharya et
al. 1999). In this 'sliding clamp' model MSH proteins survey DNA in the ADP-
bound form. When DNA mismatch is detected, it provokes ADP to ATP exchange by
the MSH subunits which causes a conformational change, leading to the formation of
a hydrolysis-independent sliding clamp in which MSH proteins encircle the DNA. In
the ATP-activated form, the sliding clamp is thought to tranduce a 'mismatch signal'
to a downstream effector such as the polymerase machinery, which controls excision
repair. In the absence of excision repair or when presented with an overwhelming
amount of DNA damage, the ATP-activated form of hMSH2-hMSH6 signals directly
to the apoptotic machinery. The bacterial MutL homologs, may serve as the ATPase
accelerating protein, which induces the hydrolysis of ATP and release of the hMSH2-
hMSH6 heterodimer from the DNA, which recycles the signalling switch. They
suggest that DNA damage may signal the apoptotic machinery directly through ATP-
activated MSH proteins thus bypassing p53. Loss of MMR would therefore prevent
the damage-induced apoptotic response enabling for improved survival of neoplastic
cells, or DNA damaged cells.
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A (III) MMR andHereditary Non Polyposis Colon Cancer (HNPCC)
Loss of MMR causes destabilization of the genome and results in high mutation rates,
particularly in microsatellite sequences in both noncoding and coding portions of the
genome. This so called 'microsatellite instability' (MSI) has been used as a marker
for loss of MMR and is also called the 'replication error prone' phenotype (RER+).
Such microsatellite sequences are found in the coding regions of the HPRT, APRT,
APC, type II TGF-5 receptor and BAX genes (Fink, Aebi et al. 1998). Mutation rates
are increased at these loci in MMR deficient cells. The majority of HNPCC cancer
cases are due to mutations in either MLH1 or MSH2 (Liu, Parsons et al. 1996).
Although the MMR system seems to be normal in the heterozygote germ line cells
containing a single functional gene copy, during carcinogenesis, the remaining wild-
type allele is somatically mutated which results in the complete loss ofMMR function
in the tumour. In addition to HNPCC, loss ofMMR occurs frequently in many types
of sporadic cancers including endometrial, small and non-small cell lung, pancreatic,
gastric, ovarian, cervix and breast cancers (Han, Yanagisawa et al. 1993; Risinger,
Berchuck et al. 1993; Merlo, Mabry et al. 1994; Shridhar, Siegfried et al. 1994;
Wooster, Cleton-Jansen et al. 1994).
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B - DNA MISMATCHREPAIR AND OVARIAN CANCER
MSI and ovarian cancer
Microsatellites are widely distributed, repetitive DNA sequences composed of short,
tandemly repeated nucleotide motifs. In some neoplasms these sequences exhibit a
form of genetic instability characterised by the gain or loss of repeat units at multiple
independent loci. These lead to a change in size of an allele in the tumour compared
to the germline allele. This is called microsatellite instability (MSI) and such tumours
are reported as showing the replication error (RER) positive phenotype. The 6
published reports on MSI in sporadic ovarian cancer are shown in table 2.
MSI for all the studies was defined as a change in size of an allele in any one of the
markers examined. The overall incidence ofMSI was found to vary between 0% and
17% of sporadic ovarian tumours. The interpretation of these varying observations is
partially confounded by the small size of the studies and the variables of family
history, tumour histology, tumour stage and type ofmicrosatellite marker studies.
Two studies found an increased incidence of MSI in endometrioid histology (5 out of
10 and 2 out of 5 samples; i.e.50% and 40% respectively) compared to other epithelial
ovarian tumour subtypes (Fujita, Enomoto et al. 1995) (King, Carcangiu et al. 1995).
King et al. also noted an increased incidence in non-epithelial subtypes (40%) but was
the only study to examine this in any detail (King, Carcangiu et al. 1995). The only
other study to quote the histology of cases showed no MSI in the two cases of
endometrioid tumour examined (Osborne and Leech 1994). If there is a higher
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incidence of MSI in endometrioid and non-epithelial ovarian tumours the lack ofMSI
found in the study by Dodson et al. may in part be accounted for by histological case
mix (i.e. if the majority of tumours were serous) (Dodson, Thibodeau et al. 1993).







































3 tetra-, 3 tri-,
6 dinucleotide
repeats
None examined Histology and stage not
quoted.



























I. Not related to
family history
7 with MSI at
tetranucleotide repeat.
Only 2 at dinucleotide
repeat.
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Ovarian tumours occur with relatively high frequency in some HNPCC families
(Lynch, Bewtra et al. 1986). It is often difficult to obtain a sufficient family history to
exclude the possibility that the cases are indeed sporadic and not familial. The only
study to examine family history in detail found no increase in MSI in the 12 cases
with a positive family history compared to the 27 cases without an affected family
member (King, Carcangiu et al. 1995). In this limited study they did not find family
history identified any HNPCC families, suggesting that the majority of familial
ovarian cancers are not related to HNPCC.
In colorectal cancer there is evidence that tumours exhibiting MSI tend to present at
an earlier stage (Thibodeau, Bren et al. 1993). In ovarian cancer the association of
MSI and stage has only been examined in 2 of the above studies. King et al. showed a
significant association ofMSI with stage I tumours (p=0.001) (King, Carcangiu et al.
1995). They found tumour associated alterations in 3 out of 4 (75%) of stage I
tumours versus 4 out of 37 (11%) of the stage II, III, and IV patients. Conversely
Fujita et al. found no overall association with stage and MSI (Fujita, Enomoto et al.
1995). On subgroup analysis they found a significant trend for MSI to be associated
with advanced stage in the 10 tumours of endometrioid type studied (p=0.025), but
the numbers were small.
A consensus has been reached in the classification of MSI in colon cancer as to the
number and type of nucleotide repeats to be used for definition of MSI (Boland,
Thibodeau et al. 1998). No such work has been done in ovarian cancer and the
consensus statement warns against extrapolation of such guidelines to other tumour
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types. In the above studies different types and numbers of primers have been used to
examine for MSI. In one study the microsatellite markers were chosen for
allelotyping of ovarian cancer and dinucleotide repeats were not specifically used
(Osborne and Leech 1994). This may account for the low figure of 8% ofMSI found.
Likewise the study that found no MSI in 60 cases, commented on the use of CA
dinucleotide repeats, but the markers which were used are not fully shown in this
study which has only been reported in abstract form (Dodson, Thibodeau et al. 1993).
In contrast 2 studies have shown an increased yield of MSI using tri- and
tetranucleotide repeats compared to dinucleotide repeats (Wooster, Cleton-Jansen et
al. 1994; King, Carcangiu et al. 1995) in ovarian cancer. In vitro observations suggest
that small mismatches and large loops resulting from slippage events at repeat
sequences may be recognised and repaired by different components of the DNA
mismatch repair machinery (Umar, Boyer et al. 1994). Small mismatches involving
only a few bases would be more likely to arise in dinucleotide repeats, whereas large
loops are more likely to result form slippage at tri- and tetranucleotide repeats.
Although dinucleotide instability has been seen in some studies (Han, Yanagisawa et
al. 1993; Fujita, Enomoto et al. 1995) the increased instability with tri- and
tetranucleotide repeats suggest that some sporadic ovarian neoplasms may be
specifically defective for large loop DNA repair activity.
None of the above studies have specifically examined the relationship of MSI and




Microsatellite instability in sporadic ovarian tumours:
• Occurs in around 10-15% of cases.
• May be more common in ovarian tumours of endometrioid and non-epithelial
histological subtypes.
• May be more common in stage I tumours.
• Is more commonly found with tri- and tetra-nucleotide than dinucleotide repeats.
• Has not been examined with regard to prognosis.
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C - LOSS OF DNA MISMATCH REPAIR AND ASSOCIATION WITH
CHEMOTHERAPYRESISTANCE
Evidence is accruing that loss of one the mismatch repair genes can also lead to
resistance to certain types of chemotherapy, including cisplatin, in mammalian cells.
The first piece of evidence was from a study in Escherichia coli into methylator
resistance (Fram, Cusick et al. 1985). They showed loss of sensitivity to cisplatin by
loss of MMR in methylase deficient cells. There are now several lines of evidence
linking loss ofMMR to cisplatin chemotherapy resistance.
C (I) In vitro evidence for loss ofMMR in cisplatin resistant cell lines.
• Acquisition of the microsatellite instability (RER+) phenolype in chemotherapy
resistant cell lines.
Anthoney et al. showed acquisition of the microsatellite instability (RER+) phenotype
in 9 out of 10 ovarian cancer cells lines with in vitro acquired cisplatin resistance
(Anthoney, Mcllwrath et al. 1996). They confirmed this microsatellite instability was
seen in a stable cisplatin resistant cell line but not the cisplatin sensitive parental cell
line suggesting this was a stable loss of MMR function and not induced temporarily
by chemotherapy. Likewise, a human ovarian adenocarcinoma cell line 2008 showed
no microsatellite instability whereas the cisplatin resistant derivative 2008A readily
showed microsatellite instability (Aebi, Kurdi-Haidar et al. 1996).
• Loss ofexpression ofMMR genes in chemotherapy resistant cell lines.
Subsequent work in independent, cisplatin resistant derivatives of a human ovarian
cancer cell line showed that acquisition of the microsatellite instability (RER+)
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phenotype was due to loss of expression of the hMLHl and hPMS2 protein subunits
of the MutLa MMR complex which occurred as a frequent event (9/10). This was
shown to be due to decreased expression of only hMLHl mRNA and not hPMS2
mRNA (Brown, Hirst et al. 1997). Similarly the cisplatin resistant ovarian cancer cell
line 2008A showed loss of expression of hMLHl protein on Western immunoblot
compared with the parental 2008 cell line (Aebi, Kurdi-Haidar et al. 1996).
Similar work on cisplatin resistant melanoma cell lines (MeWo CIS 0.01 and MeWo
CIS 1) compared to the parental cell line (MeWo) showed a 0.3 fold reduction in
hMSH2; a 0.6 fold reduction in hMLHl and a 0.7 fold reduction in hMSLI6 protein
expression by Western blot analysis respectively. On Northern blot analysis of
mRNA only the MeWoCISl cell line showed a reduction in mRNA of 0.2 fold for
hMSH2 and 0.6 fold for hMLHl compared to the parental cell line. Interestingly
neither of the cisplatin resistant cell lines showed microsatellite instability suggesting
that a reduction in MLH1 or MSH2 expression may occur that is sufficient to be
associated with cisplatin resistance but not the RER+ phenotype (Lage, Christmann et
al. 1999).
• Loss ofMMR function in chemotherapy resistant cell lines.
Deficiency in strand specific mismatch repair has been shown in two cisplatin
resistant ovarian cell lines compared to the parental cell line (Drummond, Anthoney et
al. 1996). The defect in repair of either a single G-T mispair or a -CA- dinucleleotide
insertion/deletion mismatch was evident in the resistant cell lines only when the
strand break that directs the reaction was located 3' to the mismatch. DNA repair was
restored by the addition of purified MutLa heterodimer but not the MutSa
heterodimer (Drummond, Anthoney et al. 1996).
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Similarly a cisplatin resistant derivative (A2780/CP70) ovarian cancer cell line
showed a reduction in a G:T mismatch recognition activity, by gel retardation assay,
compared to the parental cell line (Anthoney, Mcllwrath et al. 1996).
Loss of MMR has been shown to markedly increase the mutation rate at the HPRT
locus. The cisplatin resistant, hMLHl deficient, ovarian cancer cell line 2008A
showed a mutation rate at the HPRT locus that was elevated between 10.8 to 139-fold
compared to the cisplatin sensitive, hMLHl present, parental 2008 cell line. This
suggests a mutator phenotype exists due to the loss of DNA mismatch repair function
(Aebi, Kurdi-Haidar et al. 1996).
• Restoration ofMMR genes leading to restoration ofchemotherapy sensitivity.
Because it has proved difficult to transfect cell lines with MMR genes alone, much of
this work has been done using transfection of complete chromosome 3 (containing
hMLHl) and chromosome 2 (containing hMSH2). HCT116 is a human colorectal
adenocarcinoma cell line deficient in hMLHl. It has been shown that HCT116 +ch2
(hMLHl deficient) was 2 fold resistant to cisplatin compared to a subline
complemented with chromosome 3 expressing a wild-type copy of hMLHl (Fink,
Nebel et al. 1996). Likewise, the human endometrial cancer cell line HEC59, which
is deficient in hMSH2, was 1.8 fold resistant to cisplatin in clonogenic assays when
compared to a subline complemented with chromosome 2 containing wild-type
hMSH2 (Aebi, Kurdi-Haidar et al. 1996). This 2 fold resistance is of the order to be
of clinical significance.
Using isogenic strains of Saccharomyces cerevisiae it has been shown that disruption
of the MutS homologues MSH2, MSH3 and MSH6 and the MutL homologues MLH1
and MLH2 conferred a significant increase in resistance to cisplatin compared with
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the wild type. Transformation of the MLH1 gene back into the MLH1 mutant strain
led to increased sensitivity to cisplatin compared with vector-alone control (Durant,
Morris et al. 1999).
• The MMR complex hMutSa can recognise and bind to the cisplatin 1,2 crosslink.
Using binding assays with a series of duplex oligonucleotides containing a single 1,2
diguanyl intrastrand crosslink typical of cisplatin damage (Yamada, O'Regan et al.
1997) showed that human cell extracts contain factors that preferentially recognise
this type of damage. Interestingly this binding was only recognised when the
complementary strand contains T opposite the 3' and C opposite the 5' guanine in the
crosslink. In cell lines deficient in hMutSa (LoVo and DLD-1) the binding activity
was absent. Confirming this finding purified human hMutSa exhibits the same
substrate preference for platinated DNA. This data suggests that it is the hMutSa
complex that binds to the 1,2 diguanyl intrastrand crosslink (Yamada, O'Regan et al.
1997).
It has also been shown by mobility shift assays that there is formation of protein-DNA
complexes that contain hMSH2 and hMLHl when nuclear extracts are incubated with
DNA platinated with cisplatin (Fink, Nebel et al. 1996).
• Loss of MMR function leads to inability to undergo chemotherapy-induced
apoptosis.
Independent cisplatin resistant derivatives of a human ovarian cancer cell line also
lose the ability to undergo cisplatin induced apoptosis, which is associated with loss
of p53 function (Anthoney, Mcllwrath et al. 1996; Drummond, Anthoney et al. 1996).
Other cellular responses to cisplatin induced damage have been shown to be
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abrogated by loss of MMR. The cisplatin resistant, hMLHl deficient, ovarian cancer
cell line A2780/CP70 loses the ability to engage G1 and G2 cell cycle arrest after
cisplatin damage compared to the hMLHl intact parental cell line (Brown, Hirst et al.
1997). Restoration of hMLHl also leads to restoration of ability to engage G2 arrest
(Buermeyer, Van Patten et al. 1999)
• Enrichment for MMR deficient cells occurs during treatment with cisplatin.
It has been shown that treatment with cisplatin can increase the percentage of cells
with loss of MMR. Using HCT116 (a colon tumour cell line deficient in hMLHl)
sublines complemented with chromosome 2 (control hMLHl deficient) versus
chromosome 3 (hMHLl proficient) in a 95:5 ratio Fink et al. showed a 53%
enrichment, 5 days after a one hour exposure to IC50 concentration of cisplatin, for
MMR deficient cells. This enrichment increased with multiple exposures to cisplatin
by up to 77% after the fourth exposure. Enrichment was more pronounced when the
cells were exposed to an IC90 concentration of cisplatin and after the fourth cycle
there were 163% more MMR deficient cells (Fink, Zheng et al. 1997).
Using a MMR deficient (clone B) and MMR proficient (clone B/rev) pair of Chinese
hamster ovary sublines Fink et al. showed a 1.8 fold resistance to cisplatin by
clonogenic assays for clone B cells. Five days after a single 1-hour exposure to
cisplatin at an IC50 concentration, populations containing 5 or 10% clone B cells
showed enrichment for clone B cells of 81 and 75% respectively. This enrichment
was more pronounced with increased drug exposure. Following an IC90
concentration exposure to cisplatin the increases were 158 and 169% respectively
(Fink, Nebel etal. 1998).
C (II) In vivo evidence for loss ofMMR in cisylatin resistance
• In vivo resistance to cisplatin in MMR deficient tumours in mice models.
In this study MSH2-/- and MSH2+/+ embryonic stem cells were established as
xenografts in athymic nude mice. Each mouse had 2 tumours of each type. 48 hours
after implantation the animals were treated with a single LD10 dose of cisplatin. The
remaining mean volumes of the MSH2-/- tumours were statistically significantly
larger than those of the MSH2+/+ tumours (p<0.0001). This suggested that loss of
MSH2 alone resulted in a resistance to treatment with cisplatin (Fink, Zheng et al.
1997).
• Increase (enrichment) in cells with loss ofMMR in cisylatin exposed tumours.
A 5:95% ratio of Chinese hamster ovary sublines of MMR deficient (Clone B) and
MMR proficient (clone B/rev) were grown as xenografts in mice. A single LD10
dose of cisplatin enriched the tumours from 4.6% to 6.8% MMR-deficient cells. This
represented an enrichment of 48% (just significant at p=0.04) for MMR deficient cells
(Fink, Nebel et al. 1998).
An increase in the proportion of ovarian tumours negative for the hMLHl subunit has
been observed in samples taken at second look laporotomy after
cisplatin/cyclophosphamide chemotherapy (36%; 4/11) compared to untreated
primary tumours (10%; 4/39) (Brown, Hirst et al. 1997). No difference is seen in
expression of hMSH2, hMSH6 or hPMS2 by immunoblot Western analysis.
Unfortunately, in this retrospective study these samples were not paired i.e. they did
not come from the same patients pre and post chemotherapy.
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In a separate study paired ovarian cancer tumour samples were obtained prior to and
after 3 cycles of either cisplatin or carboplatin based chemotherapy in 38 patients.
The expression of hMLHl was examined using immunohistochemistry. The number
of tumour cells showing positive staining for MLH1 was scored, in decades, blindly
by an independent pathologist. 66% of the paired samples showed a reduction in
hMLHl expression after the chemotherapy (p=0.0005) (Fink, Nebel et al. 1998).
In summary, there is a growing body of evidence linking loss ofmismatch repair with
resistance to cisplatin chemotherapy, but only 2 studies suggest that this is relevant in
treatment of tumours in man (Brown, Hirst et al. 1997; Fink, Nebel et al. 1998).
C (III) Loss ofmismatch repair and resistance to other chemotherapy agents.
There are numerous studies linking the loss of mismatch repair with resistance to
other chemotherapy agents. The initial work was on the methylating agents MNNG,
MNU and the purine analogue, 6-thioguanine, and has been confirmed in newer
agents such as temozlamide. However, following the results that MMR loss was also
important in cisplatin resistance, several other drugs have been shown to have altered
chemosensitivity dependent upon MMR status. These include the cisplatin alternative
carboplatin, but interestingly not the derivative oxaliplatin. Also this includes
doxorubicin, and the topo II isomerase inhibitor etoposide. Recently the clinical
treatment of ovarian cancer has come to include taxoids as first line and topo I
isomerase inhibitors as 2nd line chemotherapy but there is no evidence that MMR
status alters sensitivity to paclitaxel or topotecan. Table 3 lists the evidence for each
of the cytotoxic drugs followed by a summary of the studies included.
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• Summary ofstudies examining chemotherapy resistance and loss ofMMR
1. (Colella, Marchinin et al. 1999) Used HCT116, a human colorectal
adenocarcinoma cell line, (hMLHl deficient) versus HCT116+chromosome 3
(hMLHl proficient). Also used A2780 (MMR proficient) versus A2780/CP70
and A2780/MCP-1 (both hMLHl deficient) versus A2780/CP70 +chromosome 3
(hMLHl proficient). Showed loss of MMR was associated with resistance to
three alkylating minor groove binders (Tallimustine, Carzelesin and CC1065) but
not to non-covalent minor groove binder PNU151807. Restoration of MMR by
chromosome transfer led to restoration of chemosensitivity to the alkylating minor
groove binders.
2. (Buermeyer, Van Patten et al. 1999) Used a mouse embryonic fibroblast cell line
(MEF) deficient in hMLHl and transfected with cDNA for hMLHl. Showed
resistance to 6-thioguanine in wild type MEF compared to hMLHl deficient MEF.
Showed some restoration of chemosensitivity to 6-TG by transfection with
hMLHl. Also showed that restoration of hMLHl restored 6-TG induced cell
cycle arrest.
3. (Lage, Christmann et al. 1999) Used MeWo, a human melanoma cell line, and
selected subclones for chemotherapy resistance. Showed loss of MMR proteins
hMLHl, hMSH2 and hMSH6 in cells resistant to etoposide and vindesine, but not
fotemustine. Showed reduction in mRNA encoding hMLHl and hMSH2 in cells
resistant to etoposide and fotemustine but only a small reduction in cells resistant
to vindesine. Interestingly did not show RER+ve phenotype in resistant cell lines
despite reductions in MMR protein expression.
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4. (Vaisman, Varchenko et al. 1998) Used several models ofMMR proficient versus
MMR deficient cells lines including: A2780 versus A2780/CP70 (hMLHl
deficient); HCT116 (hMLHl deficient) versus HCT116 +ch3 versus HCT 116
+ch2; HHUA (hMSH3 and hMSH6 deficient) versus HHUA+ch5 (hMSH3
proficient) versus HHUA+ch2 (hMSH6 proficient) and DLD-1 (hMSH6 deficient)
versus DLD-1+ch2 (hMSH6 proficient). Showed loss of MMR proteins by
Western blot in each cell line but no change in sensitivity to oxaliplatin in MMR
proficient versus MMR deficient systems. Also showed no change in DNA
replicative bypass of oxaliplatin adducts in association with loss ofMMR.
5. (Freidman, McLendon et al. 1998) Showed no significant difference in response
rate in 38 newly diagnosed malignant glioma patients treated with temozolamide
by immunohistochemistry for MMR proteins hMLHl and hMSH2.
6. (Friedman, Johnson et al. 1997) Used D-245MG, a human glioblastoma
multiforme xenograft compared to D-245MG(PR) subline. Showed loss of
hMSH2 protein and microsatellite instability in the (PR) subline compared to the
parental subline. The MMR deficient subline was resistant to procarbazine,
temozolamide, MNU, and busulfan but not to BCNU, cyclophosphamide,
topotecan, CPT-11, and 9-aminocamptothecin.
7. (Durant, Morris et al. 1999) Used a yeast model with genetic knockouts ofMMR
genes. Showed loss of MSH2, MSH3, MSH6, MLH1 and MLH2 but not PMS1
increased resistance to carboplatin 1.5 to 3.1 fold. Likewise loss of MSH2,
MSH3, MSH6 and MLH1 increased resistance to doxorubicin 2.1 to 6 fold.
Restoration of the MLH1 gene into MLH1 knockouts restored sensitivity to
doxorubicin but not significantly to carboplatin.
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8. (Moreland, Illand et al. 1999) Used the A2780/CP70 MLH1 deficient cell line
complemented by either chromosome 2 (control) or chromosome 3 (MLH1 +).
The MMR defective cell line was more resistant to MNU than the MMR
proficient cells.
9. (Umar, Koi et al. 1997) Used an endometrial tumour cell line HEC 59 (deficient
in hMSH2) and colon tumour cell line HCT15 (deficient in hMSH6) compared
with complemented cell lines containing chromosome 2 (MSH2 and MSH6
proficient). Showed that restoration of MMR restored sensitivity to MNU and
also Microsatellite stability.
10. (Mackay, Cameron et al. 2000) Primary chemotherapy with either epirubicin or
doxorubicin containing regimens in 29 breast cancer patients resulted in a
significant increase in the percentage of tumour cells with reduced hMLHl
immunohistochemical staining (p=0.01). This enrichment for loss of hMLHl was
strongly associated with poor disease free survival (p=0.0025) suggesting
chemotherapy resistance in vivo.
11. (Aebi, Fink et al. 1997) Used HCT116 (a colon tumour cell line deficient in
hMLHl) and compared sublines complemented with chromosome 2 (control
hMLHl deficient) or chromosome 3 (hMHLl proficient). Also used HEC59 (a
human endometrial adenocarcinoma cell line) deficient in hMSH2 versus a
complemented cell line with chromosome 2 (hMSH2 proficient). Showed
increased resistance to MNNG, 6-thioguanine, cisplatin, carboplatin and etoposide
with loss of hMLHl, and loss of hMSH2 but not to perfosfamide, melphalan, 5-
Flurouracil, doxorubicin or paclitaxel.
12. (Drummond, Anthoney et al. 1996) Showed loss of MLH1 protein and reduction
of hPMS2 protein in nuclear extracts of doxorubicin resistant subline (A2780/AD)
compared to parental doxorubicin sensitive cell line (A2780). Also showed defect
in strand specific mismatch repair in doxorubicin resistant cell line that was
restored by addition of purified MutLa heterodimer.
13. (Aebi, Kurdi-Haidar et al. 1996) Used 2008, a human ovarian adenocarcinoma
cell line and 2008/A, a subline selected for cisplatin resistance. Showed resistant
subline was RER+ve compared to parental subline. Also showed loss of hMLHl
protein in resistant subline. Confirmed functional loss of MMR by HPRT
mutation assay. The mutation rate was elevated 65 fold in the resistant compared
to the sensitive cell line. They showed the cell line 2008/A (hMLHl deficient)
was also resistant to MNNG but surprisingly was 2.6 hypersensitive to 6-
thioguanine compared to the parental cell line (hMLHl proficient).
14. (Fink, Nebel et al. 1996) Used HCT116 (a colon tumour cell line deficient in
hMLHl) and compared sublines complemented with chromosome 2 (control
hMLHl deficient) versus chromosome 3 (hMHLl proficient). Also used HEC59
(a human endometrial adenocarcinoma cell line) deficient in hMSH2 versus a
complemented cell line with chromosome 2 (hMSH2 proficient). Showed a 1.3
fold and 1.5 fold resistance to carboplatin in the MMR deficient cell line
compared to complemented MMR proficient cell lines HCT116 and HEC59
respectively. Showed no difference in MMR proficient and deficient cell lines in
sensitivity to oxaliplatin (also tetraplatin, transplatin, JM335 or JM216).
15. (Brown, Hirst et al. 1997) Used A2780, a human ovarian adenocarcinoma cell
line and 10 cisplatin resistant sublines and one doxorubicin resistant cell line A,
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which were shown to be deficient in hMLHl and hPMS2 protein but only hMLHl
mRNA. Showed cross-resistance to MNU and 6-thioguanine in MMR deficient
cell lines compared to MMR proficient parental cell line.
16. (Fink, Nebel et al. 1998) Used HCT116 (a colon tumour cell line deficient in
hMLHl) and compared sublines complemented with chromosome 2 (control
hMLHl deficient) or chromosome 3 (hMHLl proficient). Showed resistance in
MMR deficient cell line for carboplatin, etoposide, 6-thioguanine and (in contrast
to their earlier study) doxorubicin. Also showed enrichment for loss of MMR
cells after single treatment with these drugs. No change in chemosensitivity or
enrichment seen with melphalan, paclitaxel, perfosfamide or tamoxifen.
17. (Fink, Zheng et al. 1997) Used HCT116 (a colon tumour cell line deficient in
hMLHl) and compared sublines complemented with chromosome 2 (control
hMLHl deficient) versus chromosome 3 (hMHLl proficient). Showed lack of
enrichment for MMR deficient cells after treatment with oxaliplatin. Also showed
in nude mice transplanted with isogenic embryonic tumour cells which were both
MSH2 deficient and proficient that there was no difference according to MMR
status and response in vivo to oxaliplatin.
18. (Koi, Umar et al. 1994) Used HCT116 (a colon tumour cell line deficient in
hMLHl) and compared sublines complemented with chromosome 2 (control
hMLHl deficient) versus chromosome 3 (hMHLl proficient). Showed a 200 fold
reduced tolerance to MNNG by restoring MMR activity with chromosome 3.
19. (Carethers, Chauhan et al. 1999) Used HCT116 (a colon tumour cell line deficient
in hMLHl) and compared sublines complemented with chromosome 2 (control
hMLHl deficient) versus chromosome 3 (hMHLl proficient). Also used SW480
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(MMR proficient), LoVo and 2774 (hMSH2deficient) cell lines. Showed 28 fold
resistance in MMR deficient cell lines to 5FU compared to MMR proficient cell
lines.
D - DNA MISMA TCHREPAIR AND IMMUNOHISTOCHEMISTRY
D (I) Previous work on MMR immunohistochemistry technique
In 1995 Wilson et al. first described immunohistochemistry for MSH2 only in paraffin
embedded biopsies of the small and large intestine (Wilson, Ewel et al. 1995). They
used a rabbit polyclonal antibody to MSH2 (Oncogene) with autoclave heat antigen
retrieval at 65°C for one hour plus an overnight incubation. The colon and ileum
showed strong staining in crypts of Lieberkuhn. Proliferative perifibroblasts in colon
also showed significant presence of MSH2. They concluded that MSH2 is expressed
in highly proliferative cells of the gut. They also examined expression of RNA for
MSH2 in various normal human tissues including skin, lung, skeletal muscle, heart,
liver, spleen, thymus, prostate, testis, ovary, small intestine, colon and leukocytes by
Northern blot analysis and showed a high expression in testis and thymus.
Leach et al. followed with confirmatory study (Leach, Polyak et al. 1996). They
developed a mouse monoclonal Ab to hMSH2 (FE11) carboxyl terminal to use on
frozen tissue with an overnight incubation. They noted that MSH2 expression was
exclusively nuclear and expressed in a variety of human tissues including thyroid,
heart, smooth muscle and the germinal centres of lymphoid follicles. There was
prominent staining for MSH2 in the proliferative compartment of the epithelium of
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the digestive tract, extending from oesophagus to rectum. This was shown to be
similar to staining for Ki67. Using material from 2 patients with HNPCC, they
showed lack of staining in the adenomas and carcinomas but normal staining of the
surrounding stromal cells. Immunohistochemistry for PMS2 has proved a little more
problematic. The only report of PMS2 immunohistochemistry is by Fink et al.
examining the expression of hMLHl and hPMS2 in frozen sections of normal human
tissues (Fink, Nebel et al. 1997). They used overnight incubation with MLH1 (mouse
monoclonal; PharMingen) and PMS2 (rabbit polyclonal; Santa Cruz) antibodies.
Again they saw exclusively nuclear staining with very prominent staining in the
proliferating epithelia of the digestive tract. They were the first to show strong
staining in primitive testicular germ cells. Interestingly in the ovary they showed
staining of the nuclei of the granulosa cells and a subset of the stromal cells but the
surface epithelium, from which the majority of ovarian carcinomas are thought to
derive, and the germ cells were surprisingly non-reactive.
Conclusions
• Immunohistochemistry is feasible for MLH1 and MSH2 in paraffin embedded
material with heat antigen retrieval.
• Immunohistochemistry is feasible for PMS2 in fresh frozen material but has not
been shown for paraffin embedded material.
• MMR staining appears to be localised to the proliferative compartment in normal
human gut tissues.
• MMR staining is also seen in the proliferative compartment of normal human
thymus and testis, but not in the epithelial component of normal human ovary.
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D (II) MMR immunohistochemistry compared to microsatellite analysis
An important study by Thibodeau et al. compared MMR immunohistochemistry to
MSI and gene mutation (Thibodeau, French et al. 1996). Using heat induced antigen
retrieval they examined MSH2 (Oncogene) and MLH1 (Pharmingen) expression in 32
paraffin embedded colorectal cancer biopsies. 4 patients did not have enough material
for MSI analysis. The results are shown in table 4 below.
Table 4 - Comparison ofMSI and MMR immunohistochemistry.
Thibodeau et al
Immunohistochemistry


















Totals 14 14 28
*Detection of loss of MMR is the definition of a 'positive' test for immunohistochemistry.
They used strict criteria of complete absence of staining of tumour cells in presence of
positively staining non-neoplastic cells to be scored 'negative' for
immunohistochemistry. All 14 tumours with loss of immunohistochemical staining
were found to have MSI i.e. immunohistochemistry had a low false positive rate and
high specificity. All 9 of the MSI negative tumours had normal
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immunohistochemistry staining. However, 5 out of 14 tumours with normal
immunohistochemistry had MSI i.e. were falsely negative. Interestingly only one out
of these 5 tumours had a mutation to account for the presence ofMSI.
They also compared MMR gene mutation and immunohistochemistry and the results
are shown in table 5. Overall only 8 of the 19 MSI positive tumours had gene
mutations. Immunohistochemistry identified 7 out of these 8 with loss of staining. Of
the 7 cases* with loss of immunohistochemistry that were MSI positive but mutation
negative, 6 of these involved loss of MLH1 immunohistochemistry. One could
speculate that these mutation negative MSI tumours might be due to epigenetic factors
such as hypermethylation of the promoter to cause loss of gene function.






























Totals 14 0 5 9 28
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Bocker et al. showed that loss of immunohistochemistry depends on the degree of
MSI (Bocker, Palazzo et al. 1999). They compared staining for MLH1 and MSH2 in
45 colorectal cancer patients, either under age 50 or with a family history of HNPCC,
to microsatellite instability. They showed loss of immunohistochemical staining is
much more likely to be associated with high microsatellite instability, shown in table
6.
Table 6 - Comparison of MSI and MMR immunohistochemistry.
Bocker et a1 loss of immuno normal immuno Totals
MSI-High 14 (93%) 1 15
MSI-Low 1 (13%) 7 8
MSI-Stable
(normal)
2 (9%) 20 22
pO.OOOOl 45
Pare et al. examined the expression of MLH1 and MSH2 in paraffin embedded
material from 62 endometrial carcinomas in young patients (age < 52) (Pare, Hailing
et al. 1999). They confirmed the low false positive rate for immunohistochemistry,
shown in table 7. All the patients with no microsatellite instability had normal
immuno-histochemistry. However almost 25% of MSI positive tumours had not lost
immunohistochemistry but they did not examine for reductions in intensity or the
percentage of cells stained.
49
Table 7 - Comparison ofMSI and MMR immunohistochemistry.
Pare et al loss of immuno normal immuno Totals
MSI +ve 16 5 21
MSI-ve 0 41 41
16 46 62
Hartmann et al. confirmed that loss of immunohistochemistry is very specific for MSI
+ve tumours of the ureter and renal pelvis i.e. all MSI negative tumours show normal
immunohistochemistry for MLH1 and MSH2, shown in table 8 (Hartmann, Zanardo
et al. 1999).
Table 8 - Comparison ofMSI and MMR immunohistochemistry.
Hartmann et al loss of immuno normal immuno Totals
renal pelvis MSI +ve 3 0. 1 3
renal pelvis MSI -ve 0 34 34
ureter MSI +ve 10 2 12
ureter MSI-ve 0 19 19
13 55 68
Recently Marcus et al. have shown that immunohistochemistry for hMLHl and
hMSH2 is highly sensitive and specific for prediction of MSI in colorectal tumours,
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shown in table 9 (Marcus, Madlensky et al. 1999). They also tested 16 cases with
known germline mutations in either hMLHl or hMSH2 and showed that
immunohistochemistry for the correct MMR protein was lost in all 16 cases (100%
sensitivity).
Table 9 - Comparison ofMSI and MMR immunohistochemistry.
Marcus et al loss of immuno normal immuno Totals
MSI +ve 37 1 38
MSI-ve 0 34 34
37 35 72
There has only been one large study examining immunohistochemistry for MMR as a
surrogate test for defective mismatch repair compared to MSI (Cawkwell, Gray et al.
1999). All MSI positive tumours were identified by the immunohistochemical test for
loss of hMLHl or hMSH2, using heat activated antigen retrieval. They examined 215
MSI negative cases and found all to have positive staining for hMLHl and hMSH2,
shown in table 10. They did not compare immunohistochemistry with gene mutation.
Table 10 - Comparison ofMSI and MMR immunohistochemistry.
Cawkwell, L loss of immuno normal immuno Totals
MSI +ve 82 0 82
MSI-ve 0 215 215
82 215 297
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Combining the above studies, shown in table 11, allows us to calculate the specificity,
sensitivity and power of positive test of MMR immunohistochemistry compared to
microsatellite analysis in detection of loss ofMMR, shown in table 12.
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Table 12 - Sensitivity and Specificity ofMMR immunohistochemistry to predict MSI
Sensitivity and specificity of
immunohistochemistry

















Totals 179 393 572
Sensitivity = True +ve who are test +ve = 177/198 = 89%
All true +ve
Specificity = True -ve who are test -ve = 372/374 = 99.5%
All true -ve
Predictive power of a +ve test (i.e. loss of immunohistochemistry) =
Sensitivity x proportion of true +ve =
(Sensitivity x proportion of true +ve) + (1-specificity x proportion of true -ve)
0.89 x (198/572) ^_98.9%
(0.89 x (198/572)) + ((1-0.995) x (374/572))
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Combining the two limited studies that examined gene mutation and loss of
immunohistochemistry gives the following results, shown in table 13.
Table 13 - Combined results of MMR immunohistochemistry versus MMR gene
mutation
Gene No gene Gene No gene Totals






True positive False positive False negative True negative
Thibodeau et 7 7 1 15 30
al
Marcus et al 16 0 16
Totals 23 7 1 15 46
Using these results allows us to estimate the predictive power of MMR
immunohistochemistry compared to MMR gene mutation, shown in table 14.
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Table 14 - Sensitivity and Specificity of MMR immunohistochemistry to predict
MMR gene mutation
Sensitivity and specificity of 'Test' Totals
immunohistochemistry Immunohisotchemistry
compared to gene mutation +ve -ve
lost present
'True' +ve 23 1 24
Gene mutation Gene mutation
present




Totals 30 16 46
Sensitivity = True +ve who are test +ve = 23/24 = 95.8%
All true +ve
Specificity = True -ve who are test -ve = 15/22 = 68%
All true -ve
Predictive power of a +ve test (i.e. loss of immunohistochemistry) =
Sensitivity x proportion of true +ve =
(Sensitivity x proportion of true +ve) + (1-specificity x proportion of true -ve)
0.958 x (24/46) ^76.5%
(0.958 x (24/46) + ((1-0.68) x (22/46))
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Conclusions
• Total loss of MMR immunohistochemistry tends only to occur in MSI positive
tumours.
• Not all MSI positive tumours show complete loss of immunohistochemical
staining.
• Nearly all MSI negative tumours show normal immunohistochemical staining.
• The sensitivity of immunohistochemistry to detect loss ofMMR compared to MSI
analysis is 89%.
• The specificity immunohistochemistry to detect loss of MMR compared to MSI
analysis is 99.5%.
• The predictive power of a loss of immunohistochemistry to detect loss of MMR
compared to MSI analysis is 98.9%.
• In a limited number of patients immunohistochemistry appears to be very sensitive
(96%) compared to gene mutation analysis for loss ofMMR but not very specific
(68%). Therefore the predictive power of a loss of immunohistochemistry to
detect loss of MMR compared to loss of the MMR gene by mutation analysis is
only 77%.
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3(ii) - OVARIAN CANCER
A (I) - General introduction
Over 90% of malignant tumours of the ovary arise from the surface epithelium, and
are the subject of this thesis. The remainder of ovarian tumours arise from the stroma
and germ cells and are not further discussed. In Scotland ovarian cancer is the fourth
commonest cause of cancer related deaths (age standardized mortality of 20 per
100,000 population) and one in 70 women will develop ovarian cancer in their
lifetime (Swerdlow, Silva et al. 1998). There has been a gradual decrease in mortality
in younger age groups from ovarian cancer probably reflecting the introduction of
effective chemotherapy in the 1970s. In the cohort aged 35-44 years the 5 year
survival has improved from 35% for cases occuring in 1968-72 to 56% for cases from
1983-1987 (Swerdlow, Silva et al. 1998). However, epithelial ovarian cancer is
predominantly a disease of older women with a median age at diagnosis of 63 years.
The highly lethal nature of this tumour is related to the absence of symptoms in the
majority of women with early stages of the disease and unfortunately 70% of women
present with advanced disease.
In women presenting with symptoms of ovarian cancer an exploratory laparotomy is
often necessary for diagnosis. The pathological distinction between epithelial ovarian
cancer and other tumours is usually straightforward. The common histological types
of epithelial ovarian cancer are detailed in the table 15 below. However, there is often
heterogeneity within any given tumour. Some areas may be predominantly serous
with other areas predominantly mucinous.
Not only can there be difficulties in heterogeneity of histology there is often difficulty
in obtaining material for studies such as the current study due to the fact that surgery
may be undertaken in a wide variety of hospitals with different pathology
departments. The current study required liaison with 12 different pathology
departments throughout the West of Scotland. This can lead to variation in reporting
of histological subtypes. In this study all the blocks were subject to central review as
part of the original studies and the histology is taken from these.
Table 15 - Histological typing of epithelial ovarian cancer
HISTOLOGICAL TYPES OF MALIGNANT
EPITHELIAL OVARIAN TUMOURS
(Krigman, Bentley et al. 1994)
CLINICAL CORRELATES
Serous (Papillary) The commonest type
Endometrioid Bilateral in 10% of cases
Mucinous Often with normal CA125 levels
Clear cell Stage for stage, the worst prognosis






Once epithelial ovarian cancer has been confirmed, a total abdominal hysterectomy,
bilateral salpingo-oophorectomy, and omentectomy are usually performed,
accompanied by a careful examination of all serosal surfaces, biopsies of grossly
involved areas and collection of ascites or peritoneal washings for cytological studies.
If the disease appears to be limited to the ovary, the retroperitoneal nodes are also
examined. An attempt is made to debulk all gross disease, and the amount of residual
peritoneal or serosal implants remaining at the completion of surgery is noted (Allen,
Bak et al. 1993). The staging system defined by the International Federation of
Gynecologic Oncologists (FIGO) shown in table 16 (FIGO 1987) assumes that an
adequate staging operation, as above, has been performed.
'Advanced epithelial ovarian cancer' is taken to be stage IC or above for the
remainder of this thesis. Stage IA and IB and borderline tumours, treated by surgery
alone, will not be dealt with further.
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Table 16 - Staging system for epithelial ovarian cancer
FIGO staging system for epithelial ovarian cancer
(FIGO 1987)
Stage I Tumour limited to the ovaries
IA One ovary, no ascites, intact capsule
IB Both ovaries, no ascites, intact capsule
IC Ruptured capsule, capsular involvement, positive peritoneal washings or
malignant ascites
Stage II Ovarian tumour with pelvic extension
IIA Pelvic extension to uterus or tubes
IIB Pelvic extension to other pelvic organs (bladder, rectum, vagina)
IIC Pelvic extension, plus findings as for IC
Stage III
Tumour outside the pelvis or with positive lymph nodes
IIIA Microscopic seeding outside the true pelvis
IIIB Gross deposits <=2cm
IIIC Gross deposits >2cm, or positive lymph nodes
Stage IV Distant organ involvement, including liver parenchyma and positive
pleural cytology
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A (II) - Primary (1st line) chemotherapy
Patients who have residual disease or are at high risk of recurrence (usually stage IC
or above) are offered combination chemotherapy that includes a platinum analogue,
either cisplatin or carboplatin as standard treatment. Up until recently this would be in
combination with cyclophosphamide without doxorubicin (Anon 1994). In the light
of 2 recent large randomised trials showing an improvement in overall survival in
advanced ovarian cancer for cisplatin-paclitaxel combination compared to cisplatin-
cyclophosphamide, the current recommendation is for a cisplatin-paclitaxel
combination as first line chemotherapy (Piccart, Du Bois et al. 2000).
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B - CLINICAL PROGNOSTIC FACTORS INEPITHELIAL OVARIANCANCER
There are a large number of studies attempting to identify subgroups of patients with
good or poor prognosis in ovarian cancer using clinical factors. In one of the largest
meta-analysis of over 3,000 ovarian cancer patients in 38 trials the following were
found to be the main prognostic factors, in order of importance, predicting an
improved survival in advanced ovarian epithelial cancer (Voest, van Houwelingen et
al. 1989):-
1. Chemotherapy including cisplatin as initial treatment.
2. Residual disease of <2cm post operatively.
3. Good WHO performance status (0,1).
4. FIGO stage II/III compared to stage IV.
On multivariate analysis the type of chemotherapy and amount of residual disease
were found to be the most important factors predicting survival. In other studies
examining clinical prognostic factors histology, tumour grade, presence or absence of
ascites have also been found to be important (Malkasian, Melton et al. 1984; Neijt, ten
Bokkel Huinink et al. 1991; Kosary 1994; Makar, Baekelandt et al. 1995).
Interestingly referral to a specialist multidisciplinary (MTD) team and a specialist
gynaecologist with an interest in oncology has also been shown to improve survival
(Junor, Hole et al. 1994). The most consistent factors emerging from nearly all
studies of this type are the performance status, the size of residual tumour prior to
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chemotherapy and the FIGO stage (Neijt, ten Bokkel Huinink et al. 1991; Brinkhuis,
Meijer et al. 1995).
In view of the above, any study looking for molecular markers predictive of outcome
in ovarian cancer must try to allow for the clinical prognostic factors that are already
known.
Conclusions for collection of samples for prognostic study:
1. All patients should be treated by a MTD team, under a similar protocol.
2. All patients should receive the same chemotherapy or standard chemotherapy as
part of a protocol.
3. Full staging should have been performed by a competent gynaecologist and FIGO
stage and residual disease noted.
4. Performance status should be noted.
5. If possible, histology, grade of tumour and presence of ascites noted. In particular
tumours of borderline malignancy should be excluded.
Ultimately 75% of all patients either do not respond or relapse following cisplatin
based chemotherapy and other predictors of response or survival are needed (Neijt,
ten Bokkel Huinink et al. 1991).
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C - MOLECULAR PROGNOSTIC FACTORS IN OVARIAN CANCER
C (I) - Ovary cancer and p53 status
Somatic mutations of the p53 gene have been described in 30-70% of ovarian cancers.
An intact p53 pathway is important in cell cycle control. P53 is dramatically up
regulated after DNA damage and leads to cell cycle arrest at the Gl-S checkpoint
through activation of p21. Arrest of cell proliferation allows for the time necessary
for the cell machinery to repair DNA damage before the cells commit themselves to
mitosis, thus ensuring preservation of genomic stability. The p53 gene also plays an
important role in the activation of apoptosis. P53-dependent apoptosis is mediated by
pathways independent of p21 involving up-regulation of pro-apoptotic genes such as
bax and bcl-xs, as well as down-regulation of survival genes such as bcl-2, bcl-xi and
mcl-1 (Coukos and Rubin 1998).
• In vitro evidencefor p53 and ovarian cancer chemotherapy resistance.
Analysis of p53 status in human ovarian epithelial cell line has provided evidence that
this suppressor gene may be involved in cisplatin resistance. The experimental
development of cisplatin resistance in vitro in IGROV-1 cells (an ovarian cancer cell
line) is accompanied by the development of p53 mutation and abrogation of the
normal response to DNA damage, including up regulation of p53 and related
downstream genes such as p21 and bax (Perego, Giarola et al. 1996). The ovarian
cancer cell line A2780 carries the wild-type p53 gene (Vasey, Jones et al. 1996),
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whereas A2780-CP20 subclones displaying 20-fold increased resistance to cisplatin
were found to harbour p53 gene mutations (Skilling, Squartrito et al. 1996).
Transfection of the A2780 ovarian cancer cell line with a temperature sensitive
mutant p53 induced resistance to cisplatin; inhibited chemotherapy induced apoptosis;
and was accompanied by a delay in drug-mediated arrest in S-phase (Eliopoulos, Kerr
et al. 1995). Similarly transfection of A2780 with a dominant negative mutant p53
was followed by the development of cross-resistance to cisplatin, doxorubicin and
ionizing radiation but not paclitaxel (Vasey, Jones et al. 1996).
• P53 immunohistochemistry
The mutant p53 gene can be a dominant negative, i.e. even in the heterozygous state a
mutant p53 gene can lead to loss of p53 function as a result of inhibition of the wild-
type protein by the mutant p53 protein. P53 normally exists as a tetramer, but
participation of mutant protein forms leads to both loss of function as well as to
stabilisation of the molecule, resulting in a paradoxical nuclear overexpression of the
protein. This nuclear overexpression can be detected by positive
immunohistochemical staining.
However, not all p53 alterations lead to overexpression. Overexpression of p53
protein correlates significantly with allelic loss and missense mutations in exons 5-9
(Kohler, Marks et al. 1993) but nonsense mutations, splicing mutation, and most
deletions do not result in p53 protein accumulation (Wynford-Thomas 1992; Coukos
and Rubin 1998). The latter type of p53 mutations will lead to false negative
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immunohistochemistry results. In addition some studies show that overexpression of
p53 protein may occur without gene mutation (Kohler, Marks et al. 1993; Kappes,
Milde-Langosch et al. 1995) leading to false positive immunohistochemistry results.
Concordance of results between gene mutation detection and immunohistochemistry
(i.e. both positive or both negative) was 69% in one study (Dix, Robbins et al. 1994).
Also different immunohistochemistry techniques e.g. different p53 antibodies, antigen
retrieval techniques and fixation, will also affect p53 positivity (Lambkin, Mothersill
et al. 1994; Baas, van den Berg et al. 1996). Therefore clinical prognostic studies that
rely on immunohistochemical detection of overexpression of p53 as a marker of loss
of p53 function may be of limited significance. In an editorial on this subject Hall and
Lane conclude that 'p53 immunohistochemistry may indeed prove to be of real value
in tumour pathology - but only if pathologists take appropriated care in recording and
interpreting the results' (Hall and Lane 1994).
• Previous immunohistochemical studies with p53 and clinical outcome in
ovarian cancer
There have been 17 studies which have examined the relationship between p53
immunohistochemistry and clinical outcome in ovarian cancer patients (Marks,
Davidoff et al. 1991) (Kohler, Kerns et al. 1993) (Diebold, Baretton et al. 1996)
(Bosari, Viale et al. 1993) (Renninson, Baker et al. 1994) (Hartmann, Podratz et al.
1994) (Henriksen, Srang et al. 1994) (Sheridan, Silcocks et al. 1994) (van der Zee,
Hollema et al. 1995) (Klemi, Pylkkanen et al. 1995) (Righetti, Torre et al. 1996)
(Goff, Muntz et al. 1998) (Silvestrini, Daidone et al. 1998) (Herod, Eliopoulos et al.
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1996) (Geisler, Geisler et al. 1997) (Rohlke, Milde-Langosch et al. 1997) (Marx,
Meden et al. 1998).
The results from these studies have been confusing and contradictory. On
examination for a relationship with survival only 4 out of 9 studies were shown to
have a significant association on multivariate analysis for overexpression of p53
associated with poor survival (Klemi, Pylkkanen et al. 1995; Herod, Eliopoulos et al.
1996; Geisler, Geisler et al. 1997; Rohlke, Milde-Langosch et al. 1997). On
univariate analysis for survival 9 out of the 13 studies that investigated an association
of survival with p53 found a positive association of p53 overexpression with poor
survival. Of the 5 studies that investigated response to chemotherapy only one found
p53 overexpression was associated with a poor response to chemotherapy (Righetti,
Torre et al. 1996) and 4 found no relationship.
Some of the positive studies for p53 immunohistochemistry as a predictor for survival
on univariate analysis can be explained by the consistent finding of p53 staining being
associated with other known clinical prognostic factors. Of the 14 studies that
assessed the relationship of stage with p53 staining, 6 found an association with
positive staining and advancing stage, a known poor prognostic factor. Similarly of
the 14 studies that examined grade, 7 found that high grade of tumour (i.e. poorly
differentiated) was associated with p53 positive staining. Interestingly, 5 out of 12
studies showed a positive correlation of p53 staining with serous histology. Only 8
studies evaluated the relationship of residual disease following laparotomy with p53
staining and 3 found an association and 5 did not. No studies examined the
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relationship of p53 staining with performance status. Some studies have been limited
in their analyses due to sample size but 7 studies had over 100 patients with one study
having 284 patients (Hartmann, Podratz et al. 1994).
Technical details in the immunostaining varied considerably between studies.
Different primary antibodies, slide fixation, antigen retrieval techniques and
incubation techniques result in an inability to directly compare the various studies.
With respect to the scoring of slides only one study gave a measure of reproducibility
of scoring between 2 observers (van der Zee, Hollema et al. 1995). Many studies
used only one scorer and in only 2 studies were the scorers stated as being blinded to
clinical outcome (Kohler, Kerns et al. 1993; van der Zee, Hollema et al. 1995). Only
one study used image analysis (Geisler, Geisler et al. 1997) for scoring as opposed to
a visual technique. Different cut-off points were used for description of 'positive'
staining for p53, although the commonest approach was to classify any degree of
positive staining as positive.
Of note, there has been one important study looking not at p53 immunohistochemistry
but at gene mutations and their relationship to clinicopathological features and
outcome in ovarian cancer (Niwa, Itoh et al. 1994). In 53 patients there was an
increase in p53 gene mutations in serous and endometrioid histology (p<0.05) but no
association with age, stage, or grade of tumour. No association was found with
response to chemotherapy or overall survival and p53 gene mutation. Importantly
there have been no prospective studies examining the role of p53
immunohistochemistry as a prognostic indicator in ovarian cancer.
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C (II) - Ovary cancer and proliferation index as measured by Ki67
Proliferation is one of the most fundamental of biological processes because of its role
in growth and in the maintenance of tissue homeostasis. In tumours in particular,
proliferation has traditionally received much attention. Ki67 is a proliferating cell
nuclear antigen coded by a gene located on chromosome 10. It is correlated with the
mitotic cycles and cell growth. Ki67 increases its own expression in the last period of
S phase and more in Gl, G2 and mitosis, but is not detectable in GO i.e. it is absent in
resting or non-proliferating cells (Brown and Gatter 1990). The percentage of cells
expressing Ki67 is therefore a good surrogate marker for the proliferation index. The
Ki67 score partly correlates with other proliferation markers like %S-phase cells and
mitotic count (van Diest, Brugal et al. 1998).
There were 3 main reasons for examining Ki67 immunostaining in this study;
1. Proliferation, as measured by Ki67 antigen expression, has been shown to be an
independent predictor of survival in epithelial ovarian cancer in several studies
detailed below.
2. hMSH2 has been shown to localise in cells of the proliferating compartment in
normal tissues on immunohistochemistry (Wilson, Ewel et al. 1995; Leach,
Polyak et al. 1996).
3. It has been shown that both hMLHl and hMSH2 can bind to PCNA (proliferating
cell nuclear antigen) suggesting a link between MMR and replication (Umar,
Buermeyer et al. 1996).
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We therefore thought it was important to show that any pathological clinical
correlation of MMR proteins in ovarian cancer was independent of a relationship of
MMR protein expression with proliferation.
• The evidence for an association of Ki67, as a marker of proliferation, with
clinicalpathologicalfeatures and outcome in ovarian cancer.
The initial studies using Ki67 as a proliferation marker in ovarian cancer had to be
done on fresh frozen samples using the Dako Ki67 antibody (Jordan, Kerns et al.
1993) and therefore numbers of samples were limited. Despite this they showed a
correlation on univariate analysis of increased Ki67 expression with poor overall
survival (p<0.01). Because of the small numbers, clinical and pathological features
and therefore a multivariate analysis of survival could not be performed.
Since the development of the MIB-1 antibody, which can stain for Ki67 antigen in
paraffin embedded, historical samples, using a microwave antigen retrieval technique,
larger and more detailed studies have been performed. MIB-1 asessments in paraffin
sections are more reproducible than their counterparts in frozen sections (van Diest,
Brugal et al. 1998). The scoring system used for the 'proliferation index' has varied
between studies. Some studies have used a manual percentage positive score with or
without the help of a grid (Altavilla, Marchetti et al. 1996; Rohlke, Milde-Langosch et
al. 1997; Goff, Muntz et al. 1998). The use of a quantitative image analysis using the
CAS 200 system has been favoured by some (Jordan, Kerns et al. 1993; Kems, Jordan
et al. 1994; Layfield, Saria et al. 1997; Anttila, Kosma et al. 1998).
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With the CAS 200 system a two colour image analysis is used to calculate the
proportion of Ki67 positive nuclei in relation to the total nuclear area. This type of
image analysis measures absorbances of differentially stained cellular elements.
Firstly, the observer determines the nuclear threshold on the specimen image field
without positive stain, thus isolating nuclei from the image field. After that, the
observer sets manually the antibody boundary, using the antibody threshold function.
These nuclear and antibody thresholds are adjusted manually for every different
sample to take account for different staining. The proportion of the Ki67 positive area
in relation to the total nuclear area is then calculated on at least 10 different fields.
In analysis of association of Ki67 staining and ovarian cancer prognosis all studies
have used a cut-off point to differentiate between 'high' and Tow' proliferation.
Unfortunately the cut-off point varies from 7% in one study (Kerns, Jordan et al.
1994) up to 50% in another (Goff, Muntz et al. 1998). The reason for choice of cut¬
off is not well described in any study. The reproducibility of the scoring system used
is also not commented upon in any study. Only one study states that the slides were
scored blindly by the observer (Anttila, Kosma et al. 1998). In view of the above
there have been differences found in the outcome of the studies.
However, most studies do show a significant correlation (p<0.05) on univariate
analysis between 'high' Ki67 staining and poor overall survival (Jordan, Kerns et al.
1993; Kerns, Jordan et al. 1994; Altavilla, Marchetti et al. 1996; Layfield, Saria et al.
1997; Anttila, Kosma et al. 1998; Goff, Muntz et al. 1998). Only one study
performed a multivariate analysis for survival including all the known clinical and
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pathological prognostic factors for ovarian cancer and again showed a correlation of
Ki67 with overall survival (p=0.04) (Anttila, Kosma et al. 1998). This study also
showed an association of 'high' Ki67 staining and poor progression free survival on
univariate (p=0.0024) but not multivariate analysis. In contrast one study of 104
patients showed no correlation of Ki67 staining with overall survival but this was the
only study to use manually assessed groups for percentage staining of 0-20%; 21-50%
and over 50 (Rohlke, Milde-Langosch et al. 1997).
Some studies have looked at the correlation of Ki67 staining with clinical and
pathological prognostic factors in ovarian cancer. On the whole these have been
negative for age (Layfield, Saria et al. 1997); grade of tumour and stage (Jordan,
Kerns et al. 1993; Kerns, Jordan et al. 1994; Layfield, Saria et al. 1997). However
only one study had a large number of patients (n=316) and did show an association of
increased Ki67 staining and high grade (p=0.001) and increasing stage (p<0.001) but
no association with age, histology or residual disease (Anttila, Kosma et al. 1998).
Two studies have examined the relationship of proliferation index as measured by
Ki67 staining and response to chemotherapy by second look laparotomy results. They
both showed no association (Layfield, Saria et al. 1997; Rohlke, Milde-Langosch et
al. 1997).
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3 (in) - CISPLATIN CHEMOTHERAPY RESISTANCE
A - INTRODUCTION
Cisplatin is the mainstay of treatment in a number of human cancers, shown in figure
1. It was first noted by Rosenberg in 1965 that growth of Escherichia coli was
inhibited in a continuous culture apparatus containing platinum electrodes. This was
found to be due to cA-dichlorodiammineplatinum, hereafter called cisplatin. By 1973
it was clear that cisplatin had antitumour activity in a number of human cancers.
Initial enthusiasm was dampened by renal toxicity until prehydration and prolonged
infusion were shown to be an effective way of ameliorating the nephrotoxic side
effects of cisplatin in 1977 (Rosenberg 1984).




Cisplatin preferentially forms intrastrand crosslinks with G-C rich regions of DNA
(Stone, Kelman et al. 1974). Cisplatin forms a closed ring adduct with both N7 and
06 of guanine. The 06 position of guanine is normally involved in hydrogen bonding
capacity to cytosine and this is blocked. On base pairing during cell replication the
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guanine will then mispair with thymine if the adduct is not removed before replication
occurs (Rosenberg 1984).
Since these studies it has been shown clinically that the amount of platinum-DNA
adduct formation is directly related to the antitumour effects of cisplatin. In one phase
I study of cisplatin and carboplatin in 24 different tumour types it was shown that the
platinum-DNA adduct level measured by atomic absorbance spectroscopy (AAS) was
directly related to disease response regardless of the tumour type (p=0.0004) (Reed,
Parker et al. 1993).
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B -MECHANISMS OF CISPLATINRESISTANCE
Considerable effort has been invested in defining the cellular and molecular
mechanisms responsible for resistance to cisplatin. Most published data are derived
from preclinical model systems, where a large number of potential resistance
mechanisms have been identified. However not all these mechanisms may be in
important in vivo. The mechanisms identified can be broadly grouped into 2
categories;










B (I) - Altered accumulation
The mechanism by which cisplatin enters cells is still not clearly defined. It is
thought that it may enter cells via transmembrane channels. Decreased accumulation
of cisplatin into cells is common in cell lines selected for cisplatin resistance in vitro
(Gately and Howell 1993). However, this reduced accumulation does not generally
correlate with the magnitude of resistance observed. Thus, it is probable that
additional mechanisms are involved.
B (II) - Thiols
Cytosolic inactivation is another mechanism that can prevent cisplatin from reacting
with intracellular target molecules. Intracellular sulphydryl compounds have been
proposed to function in this manner (glutathione (GSH) and metallothionein (MT)).
GSH covalently binds cisplatin at physiological concentrations (Dedon and Borch
1987) and can inhibit conversion of platinum-DNA monoadducts to potentially
cytotoxic crosslinks (Eastman 1987). Linear correlations between GSH levels and
cisplatin resistance have been reported in ovarian cancer cell lines and in human
ovarian tumour biopsies (Perez 1998). In contrast, levels of glutathione S-transferase
(GST), which are responsible for maintaining levels of GSH in cells, have been shown
to be reduced in malignant ovarian tumours after chemotherapy with cisplatin (van
der Zee, van Ommen et al. 1992).
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Metallothionein is a low molecular weight, cystein rich metalloprotein that can react
directly with cisplatin (Pattanaik, Bachowski et al. 1992). However, while
metallothionein expression has been associated with cisplatin resistance in some
models, no association has been seen in other models (Perez 1998).
B (III) - DNA repair
Nucleotide excision repair (NER) is important in the repair of bulky covalent lesions
within the DNA, such as platinum-DNA lesions (Reed 1998). In human ovarian
cancer patients it has been shown that high tumour tissue levels of ERCC1 mRNA
(critically involved in NER) are associated with clinical resistance to platinum
(Dabholkar, Bostick-Bruton et al. 1992). A large body of evidence suggests that NER
is the predominant pathway that repairs platinum DNA adducts in cellular DNA
(Reed 1998).
B (IV) - DNA damage tolerance and M.MR activity
In a series of unrelated human ovarian carcinoma cell lines several potential resistance
mechanisms to cisplatin were examined (Johnson, Laub et al. 1997). It was found that
DNA damage tolerance was strongly correlated with cisplatin sensitivity, whereas no
correlation was apparent for platinum accumulation, GSH levels, or platinum DNA
adduct repair. This suggests that although DNA repair (by NER) is important
quantitatively, it is DNA damage tolerance that is potentially important in determining
cisplatin resistance. The mechanisms that confer tolerance to DNA damage are still
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incompletely defined and are discussed in detail in the section on loss ofMMR and
cisplatin resistance.
B (V) - HMG proteins
The high-mobility-group (HMG) proteins are a multifunctional family of small non¬
histone chromatin-associated proteins. These proteins are involved in gene regulation
and maintenance of chromatin structure. Several HMG-family proteins specifically
recognise cisplatin-DNA adducts (Perez 1998). The product of the Ixrl/ORDl gene,
in yeast, is a HMG protein that specifically binds cisplatin-DNA adducts. Compared
with parental strains Ixrl deletion mutants contain fewer platinum-DNA adducts and
are 2-fold resistant to cisplatin (Brown, Kellet et al. 1993). The full significance of
HMG proteins in mammalian cells is not yet known.
B (VI) - Apoptotic response
The potential of altered capacity to undergo apoptosis in causing resistance to
cisplatin is being increasingly studied. One critical regulator of apoptosis in response
to cisplatin is p53 (Kastan, Onyekwere et al. 1991). Direct evidence for the role of
p53 in cisplatin resistance comes from experiments using p53 genetic suppressor
elements (GSE). By using GSE to cause a decrease in p53 protein levels and loss of
p53 function, (including cell cycle arrest and apoptosis), there was up to an 8-fold
increase in cisplatin resistance in the A2780 ovarian carcinoma cell lines transfected
with GSE (Gallagher, Cairney et al. 1997).
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Conclusions
A substantial number of mechanisms have been suggested to explain resistance to
cisplatin chemotherapy. Many of these mechanisms rely on data from in vitro models
and it is difficult to know how much influence they may have in clinical resistance in
humans. However, an improved understanding of cisplatin resistance would be useful
in a number ofways:
1. To predict clinical response to chemotherapy. This would allow prediction of
patients requiring modulation of their therapy.





4 rn - PATIENTS FOR IMMUNOHISTOCHEMICAL ANALYSIS
All patients were selected from 3 previous clinical trials in ovarian cancer performed
at the Beatson Oncology Centre, Glasgow since 1989, from whom histological blocks
could be obtained. Data prospectively collected on these patients included; FIGO
stage at diagnosis (International Federation of Gynaecology and Obstetrics) (FIGO
1987), performance status (PS); residual disease at primary operation (either <2cm or
>2cm); histology; age; response to chemotherapy; time to progression and overall
survival. All patients had given written informed consent for data collection as part of
these trials, which were all approved by the local ethics committee. All patients had a
histological diagnosis of ovarian adenocarcinoma and were treated with primary
chemotherapy regimens containing cisplatin. In one trial patients were randomised to
receive either high or low dose cisplatin (100 or 50 mg/m ) respectively with 750
mg/m2 cyclophosphamide (Kaye, Paul et al. 1996). In the second trial patients all
9 9 •
received 100 mg/m" cisplatin and 750 mg/m cyclophosphamide and were randomised
to receive placebo or nimodipine (Cassidy, Paul et al. 1998). In the third trial all
2 , 2
patients received 75mg/m cisplatin and were randomised to receive Taxol 135mg/m
or cyclophosphamide 750mg/m" (Stuart, Bertelsen et al. 1998). Response to
chemotherapy was assessed according to WHO criteria (Miller, Hoogstraten et al.
1981).
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58 patients were included in the study. Their median age was 56 (range 27-71). Their
other characteristics are shown in table 17. Fifteen patients are still alive with a
median follow up of 94 months (range 32-112 months). Six of these 15 have
progressed. For each patient all the available haematoxylin and eosin stained sections
were reviewed and a representative block was selected for further study.
Table 17 - Patient characteristics
(N=58) N= %
Chemotherapy Cisplatin (5 (^/Cyclophosphamide1 25 43
Cisplatin (lOOyCyclophosphamide1 24 41
Cisplatin (100)/Cyclophosphamide 3 5
Cisplatin (75)/ Taxol3 3 5
Cisplatin (75)/ Cyclophosphamide 3 5




Performance Status 0 19 33
1 34 59
2 5 9
Residual Disease <2cm (1) 20 34
2cm or greater (2) 38 66
Histology Serous cystadenocarcinoma 17 29
Adenocarcinoma 13 22
Papillary adenocarcinoma 19 33
Mucinous cystadenocarcinoma 3 5
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Endometrioid carcinoma 3 5
Clear cell carcinoma 2 3
Unknown 1 2
References; 1 = (Kaye, Paul et al. 1996); 2 = (Cassidy, Paul et al. 1998); 3 = (Stuart,
Bertelsen et al. 1998)
As part of the study 114 paraffin embedded blocks of tissue were sectioned and
stained for the 4 antibodies; MLH1, MSH2, Ki67 and p53. 4 blocks had insufficient
tumour material for scoring. Therefore 110 blocks were able to be scored. 13 blocks
were repeats from the same patient at the same operation and are discussed in detail
elsewhere. Therefore a total of 97 blocks were included in the study from a total of
63 patients.
Of the total 97 number of blocks, 58 were from chemonaive patients at their initial
diagnostic laporotomy. Five patients had multiple post-chemotherapy operations and
therefore the remaining 39 post-chemotherapy blocks were from 31 patients. In 5
patients with post-chemotherapy blocks, the original pre-chemotherapy specimens
could not be recovered from the relevant pathology departments. Therefore pre- and
post-chemotherapy paired samples are only available in 26 patients.
Out of an attempted 1166 slides only 880 slides were successfully stained and suitable
for scoring i.e. a success rate of 75.5%. Failure of immunostaining was most often
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due to lack of positive staining in the relevant control slide. In this situation the
complete run was abandoned. The causes for variability in immunohistochemistry are
numerous and attention to detail is the key. Timings must be accurate and the slides
must not be allowed to dry out at any time.
4 (ii) - STATISTICAL METHODS
The associations between MMR, p53 and Ki67 scores were examined using
Spearman's rank correlation coefficient (Conover 1980). The association of these
scores with stage and histology were examined using Kruskal-Wallis one-way
analysis of variance (Conover 1980) (this corresponds to the Mann-Whitney U test
when there are only two groups).
Survival and progression times were measured from the date the patients were
recruited into the respective trials. For the survival analyses only cancer deaths were
considered as events, deaths from other causes were treated as censoring events. The
Cox proportional hazards model (Parmar and Machin 1995), stratified for type of
chemotherapy, was used to analyse these end-points. MMR, p53 and Ki67 scores
were examined individually and then in multivariate models including the established
prognostic factors of stage, extent of residual disease and performance status. P-
values for hazard ratios are from the associated likelihood ratio test. The Kaplan-
Meier method (Parmar and Machin 1995) was used for the survival plots.
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Response data (complete/partial versus stable/progression) was examined using
logistic regression (Armitage and Berry 1987). The type of chemotherapy was
included in all the logistic regression models. MMR, p53 and Ki67 scores were first
examined individually and then in models containing the three prognostic factors. P-
values for odds ratios are from the associated likelihood ratio test.
Weighted kappa (Fleiss and Cohen 1973) values were used for measuring inter- and
intra-observer agreement on MMR and p53 scores. The intra-observer agreement for
Ki-67 scores was measured using an intra-class correlation coefficient. The inter-
observer agreement was obtained by comparing the two observers' scores for the
same slide. The intra-observer agreement was measured by comparing the same
observer's scores on the same slide on two different occasions at least 6 months apart.
The intra-slide agreement was measured by comparing the same observer's scores on
different slides from the same patient.
All P-values quoted are two-tailed.
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Chapter 5 -METHODS AND SCORING FOR
IMMUNOHISTOCHEMISTRY
1 - IMMUNOHISTOCHEMISTRY
1A - IMMUNOHISTOCHEMISTRY TECHNIQUE
I. Introduction
The loss of function in any of four human DNA mismatch repair genes, (hMSH2,
hMLHl, hPMSl and hPMS2) is thought to lead to deficient mismatch repair ofDNA
in the somatic cells leading to increased mutations and thereby cancer development.
Microsatellite instability (MSI) detected by PCR analysis has to date been the
hallmark of loss of the function of these genes. Western and Northern blotting has
confirmed the associtation of loss of mismatch repair (MMR) protein expression with
microsatellite instability. However, this technique relies on fresh samples for DNA
extraction and requires a normal tissue sample. Expression ofMMR proteins can now
be examined in both fresh and archival paraffin embedded tissue samples using
immunohistochemical techniques.
II. Streptavidin-biotin immunoperoxidase method
Immunohistochemistry has undergone numerous refinements over the past 20 years
and is now routinely performed for both diagnostic and prognostic information on
patient tissue samples in pathology laboratories. Numerous kits are available
commercially and choice is normally based on local experience and the cost of the
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monoclonal antibodies used. The technique used below employs the streptavidin-
biotin technique coupled to peroxidase activity for use as a label (Hsu, Raine et al.
1981). This relies on the markedly high affinity of avidin, a 68, 000 mw glycoprotein,
for the small molecular weight vitamin, biotin. Because this affinity is over one
million times higher than that of antibody for most antigens, the binding of avidin to
biotin is essentially irreversible. In addition to this high affinity, the biotin/avidin
system can be effectively exploited because avidin has four binding sites for biotin
and most proteins (including antibodies and enzymes) can be conjugated with several
molecules of biotin. These properties provide the potential for macromolecular
complexes to be formed between avidin and biotinylated enzymes.
A small amount of unlabelled primary antibody when bound to the antigen of interest
in the tissue then binds a biotinylated secondary antibody and subsequently a
preformed avidin and biotinylated horseradish peroxidase macromolecular complex.
Diaminobenzidine (DAB) is then used as a substrate for the bound antibody complex
that produces a brown colour after undergoing oxidation. If no primary antibody is
bound to the tissue there will be no peroxidase activity and the tissue will not stain
brown with DAB. In order to visualise negative tissue samples they are
counterstained with a routine haematoxylin stain (blue). The method below is divided
into several steps for clarity. The whole procedure should take approximately 6 hours
for 20 slides.
This technique was shown to be superior to the previously used PAP (peroxidase-
antiperoxidase) method and allowed the use of antibodies diluted 20 to 40 times. The
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use of low concentrations of primary antibodies minimises background staining and
increases method-specificity.
III. Antigen retrieval
At the time of starting immunohistochemical analysis for MMR proteins as part of
this study there had been no publication on the use of antibodies for staining paraffin
embedded material and a therefore it was necessary to develop a protocol.
Microwaving as a technique for exposing antigens to the antibodies has been
developed over the last 14 years (Leong 1996) and was known to be a good technique
for both p53 and Ki67 immunohistochemistry. Tissue sections fixed in formaldehyde
and then embedded in paraffin often show a reduction in and sometimes loss of
immunoreactivity for many antigens. This is thought to be due to cross-linking of
reactive sites within the same protein and between different proteins via methylene
bridges. Calcium ions may also play a role. Attempts to unmask antigens have often
been based on pre-treatment of sections with proteolytic enzymes e.g. trypsin. (See
review by (McNicol and Richmond 1998)). Shi et al. showed that the use of
microwave heating improved the staining in 39 of 52 antibodies studied (Shi, Key et
al. 1991). The energy from heating disrupts the protein-protein crosslinks and may
also break down links between calcium ions and amino acids. Heating can be
achieved by various methods including microwave, water bath, wet autoclaving or
pressure cooker. There has been a suggestion by one group that autoclaving is to be
preferred to microwave as they showed a consistent loss ofmorphology (swollen cells
and reduced mitotic index; p<0.001) on slides subjected to microwave compared with
autoclaving or no heating (Hunt, Attanoos et al. 1996). However, the study was only
on 6 cases of non-Hodgkin's B cell lymphoma and has not been repeated in other
tissues. Therefore the heating method chosen often depends on local availability and
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experience. The slides must be heated in aqueous solutions and the pH of the buffer is
often of importance (Shi, Imam et al. 1995). The best results have been reported
using citrate buffer at pH 6.0 or Tris-HCl at pH7-8. For p53 and Ki67 the optimum
retrieval strategy is the use ofmicrowave heating and citrate buffer at pH 6.0 (Taylor,
Shi et al. 1994).
Varying lengths of time of microwaving were used to optimize positive staining and
reduce any false positive staining or loss ofmaterial from the slide. Other techniques
available to encouraging binding of the primary antibody to the slide include
overnight incubation; 0.05% saponin incubation for 30 minutes and 0.1% trypsin
incubation at 37 C for 30 minutes. Results of these different techniques are shown in
table 18.
IV Primary antibodies used
As no technique was previously described for MMR protein immunohistochemistry
on paraffin embedded material, varying dilutions of antibody were used to optimize
positive staining and reduce background staining with all the antibodies used. Results
are shown in table 19. Each optimization was repeated at least twice until
reproducible results were obtained. Marked variability with both false positive and
negative staining was noted with PMS2 despite 9 separate attempts to optimize
conditions. Of the 215 tumour slides stained for PMS2 in 13 separate runs only 50
slides (23%) could be scored from 4 of the runs. In view of the unpredictability of the
staining, PMS2 was excluded from the antibodies reported in the final results.
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A. Anti-hMLHl. Clone G168-15. PharMingen®. This anti-human
mouse antibody was purified from hybridoma tissue culture
supernatant by Protein G affinity chromatography. Full-length human
recombinant MLH1 was expressed as a maltose binding-MLHl fusion
protein, affinity purified and used as immunogen. The resulting
antibody recognizes human and mouse MLH1 (Baker, Plug et al.
1996).
B. Anti-hMSH2. Clone FE11. Calbiochem®. This anti-human mouse
monoclonal antibody was generated by immunizing BALB/c mice with
a carboxyterminal fragment of the human MSH2 protein and fusing
with SP2/0 mouse myeloma cells.
C. Anti-hPMS2. Clone 9. Calbiochem®. This anti-human mouse
monoclonal antibody was generated by immunizing CB6 F1 mice with
full length PMS2 protein expressed in E. coli and fusing with SP2/0
mouse myeloma cells. The epitope is unknown.
D. Anti-p53. Clone DO-1. Calbiochem®. This anti-human mouse
monoclonal antibody recognises an epitope on residues 21-25 of
human p53. It recognises both wild type and mutant human p53. It
was generated by immunizing BALB/c mice with recombinant human
wild type p53 protein and fusing splenocytes with mouse myeloma
cells (Vojtesek 1992).
E. Anti-Ki67. This is a polyclonal antibody developed from rabbits
immunised with a synthetic peptide deduced from the human cDNA
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sequence coding for the Ki67 antigen. It detects the native as well as
recombinant parts of the human Ki67 antigen in different test systems.
It has the advantage of being able to detect the Ki67 antigen in
routinely processed, paraffin wax embedded material. (Key, Peterson
et al. 1993). The Ki67 antigen is present in Gj, S, G2 and M phases of
the cell cycle but is absent in Go. Because of this Ki67 is a good
estimation of the growth fraction as it is only present in proliferating
cells and is absent in quiescent cells (Gerdes, Li et al. 1991). As this is
a rabbit antibody it can be used for double labelling experiments with
mouse antibodies.
V. Materials Using Vectastain® Elite ABC Kit (See Note 4)
A. Stable Solutions for immunostaining: All stable at 20°C.
1. Phosphate Buffered Saline (PBS)
2. 0.1% hydrogen peroxide (per 1 litre): 1 ml 100 vol. hydrogen
peroxide + 1 litre distilled water
3. lOmM Sodium tricitrate buffer (per 1 litre): 2.94g sodium
tricitrate + 1 litre distilled water. Adjust to pH 6 with HC1
4. Antidote to DAB (per 100 mis): 3g potassium permanganate
(KMnOzj) + 2g sodium carbonate (NaiCOs) + 100 mis distilled
water
B. Unstable Solutions for immunostaining: Keep on ice and make up
fresh. Solutions stain approximately 20 slides (See Note 5).
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1. Blocking Serum (Vectastain® Yellow - lOmls): 10 mis PBS +
150 pi Normal Horse Serum (i.e. 3 drops yellow block)
2. Biotinylated Antibody (Vectastain® Blue - lOmls): 10 mis PBS
+ 150 pi Normal Horse Serum (i.e. 3 drops yellow block) + 50
pi biotinylated anti-mouse IgG (i.e. 1 drop blue block). Note
for Ki67 use biotinylated anti-rabbit IgG
3. ABC reagent (Vectastain® Grey). Make up 30 minutes before
use. 5 mis PBS + 2 drops solution A + 2 drops solution B
4. DAB diaminobenzidine tetrahydrochloride (per 5mls): 5 mis
distilled water + 2 drops Vectastain® buffer + 2 drops hydrogen
peroxide + 4 drops Vectastain® DAB reagent. Note - possible
carcinogen - use gloves
C. Primary antibodies: (per 2 mis = approx. 20 slides), (See Note 6+7)
1. Anti-hMLHl: 20 pi MLH1 antibody (500 pg/ml purified anti-
human mouse monoclonal IgG, clone G168-15, PharMingen®,
stock solution kept at 4°C) + 1980 pi PBS. i.e. 5 pg/ml solution
or 1 in 100 dilution
2. Anti-hMSH2: 20 pi MSH2 antibody (100 pg/ml purified anti-
human mouse monoclonal IgG, Ab-2 clone FE11,
Calbiochem® stock solution kept at 4°C) + 1980 pi PBS. i.e. 1
pg/ml solution or 1 in 100 dilution
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3. Anti-hPMS2: 40 pi PMS2 antibody (100 pg/ml purified anti-
human mouse monoclonal IgG, Ab-1 clone 9, Calbiochem®
stock solution kept at 4°C) + 1960 pi PBS. i.e. 2 pg/ml solution
or 1 in 50 dilution
4. Anti-Ki67: 10 pi Ki67 antibody (250 pg /ml purified anti-
human rabbit polyclonal IgG, Dako® stock solution kept at
4°C) + 1990 pi PBS. i.e. 5 pg/ml solution or 1 in 50 dilution
5. Anti-p53: 40 pi p53 antibody (100 pg/ml purified anti-human
mouse monoclonal IgG, Ab-6, Oncogene® stock solution kept
at 4°C) + 1960 pi PBS. i.e. 2 pg/ml solution or 1 in 50 dilution
D. Solutions for counterstaining:
1. Haematoxylin: Harris formula filtered before use, Surgipath®
2. 100%ethanol
3. 70%ethanol
4. Histo-clear®, Fischer Scientific Ltd.
5. Scott's Tap Water: 1 in 10 dilution in distilled water of
Surgipath® Scott's tap water substitute. Warning: can cause
skin irritation - use gloves
6. Acid Alcohol: 10 mis concentrated hydrogen chloride (specific
gravity 1.16 g/ml - approx. 33%) in 990 mis 70% ethanol
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7. Hystomount®, Hughes and Hughes Ltd.
Method
A. Dewaxing of slides. In a laminar flow hood (See Note 8).
1. Place slides in metal rack (maximum 20). Wash in bath of
Histo-clear for 20 minutes
2. Rinse in bath of 100% ethanol for 1 minute (See Note 9)
3. Rinse in bath of 70% ethanol for 1 minute
4. Rinse in tap water for 1 minute
5. Wash in bath of PBS for 5 minutes (See Note 10)
B. Removal of endogenous peroxidase activity (See Note 11)
1. Wash in bath of 0.1 % hydrogen peroxide for 20 minutes
2. Wash in bath of PBS for 5 minutes
C. Antigen retrieval (See Note 12)
1. Fill microwave box with 750 mis of sodium tricitrate buffer
(See Note 13)
2. Place slides in plastic rack and place rack into box, cover with
cling film, pierce 3 times
3. Microwave on full power (650W microwave) for 15 minutes
(See Note 14)
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4. Leave to cool for 20 minutes
D. Isolate the tissue section (See Note 15)
1. Wipe each slide in turn around tissue section with tissue paper
to dryness.
2. Circle tissue section with 5mm margin with PAP-pen
E. Vectastain® ABC technique
1. Fill bottom of immunostaining box with damp tissue paper (See
Note 16). Place slides one at a time into immunostaining box.
Cover tissue section with 3-5 drops (approx. 100-200 pi) of
yellow block and leave for 20 minutes
2. Tap off yellow block (blocking antibody), one slide at a time
and cover tissue section with 100 pi, (2-3 drops) of primary
antibody of interest (i.e. hMLHl, hMSPI2, or hPMS2). Leave
for 30 minutes
3. Place slides in metal rack and wash in PBS for 5 minutes
4. Place slides into immunostaining box and cover tissue section
with 3-5 drops (100-200 pi) of blue block (biotinylated
antibody). Make up ABC solution at the point and leave for 30
minutes
5. Place slides in metal rack and wash in PBS for 5 minutes
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6. Place slides in immunobox and cover tissue section with 3-5
drops (100-200 pi) of grey block (ABC reagent). Leave for 30
minutes
7. Place slides in metal rack and wash in fresh PBS for 5 minutes
8. Place slides in immunobox and cover tissue section with 3-5
(100-200 pi) drops of DAB (See Note 17). Leave for 10
minutes
9. Place slides in metal rack and wash in PBS for 5 minutes
10. Use 5 mis of antidote to DAB over the immunobox
F. Counterstain with haematoxylin. In a laminar flow hood (See Note 8).
1. Rinse in tap water
2. Wash in haematoxylin for 60 seconds (See Note 18) and then
rinse in tap water
3. Rinse in acid alcohol for 2-10 seconds (See Note 18) and then
rinse in tap water
4. Wash in Scott's tap water for 60 seconds and then rinse in tap
water
5. Wash in 70% alcohol for 60 seconds
6. Wash in 100% alcohol for 60 seconds
7. Place in Histo-clear© for at least 5 minutes
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G. Mount slides (Perform in laminar air flow hood)
1. Place 20 coverslips on filter paper and place a drop of
Hystomount® on each coverslip (See Note 19)
2. Take each slide in turn and wipe off excess Histo-clear®
around tissue section. Place tissue section face down onto
coverslip and leave for 10 seconds
3. Invert slide and coverslip so that the coverslip is face up and
leave to set for at least one hour
VII. Notes
1) Tissue sections will be brown if the protein is present (positive) and blue if
negative. It is essential for each run to include a known positive and negative
slide control. We used sectioned paraffin embedded samples of cell lines with
known mismatch repair protein status, i.e. Ovarian A2780 as a positive control for
MLH1, PMS2 and MSH2, Ovarian A2780/CP70 for hMLHl and hPMS2 negative
(Anthoney, Mcllwrath et al. 1996) and Colon LOVO 1 as negative for hMSH2
(Umar, Boyer et al. 1994).
2) To immunostain fresh fixed samples omit step one and place directly into PBS.
Start with removal of endogenous peroxidase activity (step 2 in method).
3) Be gentle with the slides. The tissue sections can wash off if moved in solutions
too vigorously. Using APES (Sigma) coated slides to mount the tissue sections
will help them to stick.
4) The use of the Vectastain® Elite ABC kit is a personal choice. It does allow a
small amount of expensive antibody to be used for a positive result.
5) Vortex all solutions before using to ensure even mixing.
6) Different batches of primary antibody give variable staining. With a new batch it
is a good idea to run positive and negative controls with dilutions suggested but
also 50% and 200% of these. We have found hPMS2 in particular to vary and
require different dilutions depending on the batch.
7) To prevent variability of staining try to keep the stock solutions of primary
antibody on ice at all time and return to storage as promptly as possible.
8) Histo-clear® and Hystomount® give off noxious fumes. Perform all steps
involving these in a laminar flow hood.
9) Check the slides when in 100% ethanol at step lc for dewaxing. If they are
adequately dewaxed the section will be the shape of the tissue section. If they are
not adequately dewaxed the section will still be the square shape of the original
paraffin block. If this is the case place back into the Histo-clear® for another 10
minutes and check again. Better to check at this stage than to perform the whole
immunostain and find out at the end it has not worked due to persistent wax!
10) When washing in PBS place the metal rack with the slides into a glass bath
containing enough PBS to cover the tops of the slides (usually 350mls). Place the
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bath on a rocker table for the 5 minutes to ensure even washing. Change the PBS
after each wash ideally, but certainly alter the peroxide step and the grey block to
prevent false positive staining.
11)All tissue sections of interest must be checked for endogenous peroxidase activity
(which will give a false positive result). Normally the 0.1% hydrogen peroxidase
step should solve this problem but it is worthwhile checking each block by
running a slide through the whole immunostain leaving out the primary antibody
step. This slide should be negative (blue) if there is no endogenous activity.
12) We have tried different forms of antigen retrieval with saponin, trypsin and
different times of microwaving and found 15 minutes in a microwave to give the
most consistent results.
13) Make sure there is enough buffer in the microwave box so that the tops of the
slides are covered even after 15 minutes of boiling. If this is a problem, perform
the microwaving in 3 separate 5-minute steps and top up with buffer after each 5
minutes. If the slides do dry out there will be brown 'hot spots' as artifact on the
final slides. Use a microwave with a turntable to prevent "hot spots' and place the
box eccentrically on the table, not in the middle.
14) Watch yourself with the microwave step. The buffer is boiling hot after 15
minutes in the microwave. Use protected oven-gloves to remove the box from the
microwave and leave the cling film on until it is cooler.
15) The PAP-pen step allows you to use smaller amounts of primary antibody and
prevents drying out of the tissue sections. After each step in the immunobox
double check each slide to make sure the solution is up to the edge of the circle
drawn with the PAP-pen.
16) It is critical to consistent immunostaining not to allow the tissue section on the
slide to dry out at any stage. This entails covering each slide with the next
solution on a one by one basis. Do not be tempted to take all 20 slides out of the
bath, place into the immunobox, and then cover with solutions. They will dry out
giving artifact staining on the final slide. Ensure the immunobox is kept humid by
lining the bottom with tissue paper soaked in warm water and cover the box with a
plastic lid during the incubation times for the slides.
17) DAB is a potential carcinogen. Always use gloves when handling and soak all
equipment which touches DAB in an equal amount of antidote afterwards for at
least 30 minutes.
18) The depth of counterstain is of personal choice. The slides will be made bluer by
leaving in haematoxylin for longer (step 6b) or leaving in acid alcohol, which
leaches out the colour (step6d), for a shorter time.
19) Using too much Hystomount® will make the final slides messy to handle. Using
too little might allow the tissue section to dry out with time. The ideal amount
spreads from a central drop to cover the square of the coverslip in about 10
seconds. The amount to use will vary with the size of the coverslip. Always
choose a coverslip size that adequately covers the tissue section.
20) When the slides are prepared from the paraffin embedded material they loose
antigenicity and will stain false negative (blue) over a period ofmonths, if stored
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at room temperature (Jacobs, Prioleau et al. 1996). Store prepared slides at 4°C
prior to immunostaining.
21) Scoring the immunostain is a matter of personal preference. It is usual for each
slide to be scored for both the intensity of the stain and the % of cells stained.
Automated systems e.g. CAS system, exist for automated counting of the % of
cells stained. It is good practice for the slides to be independently scored by at
least 2 observers, blinded to any clinical information. Inter-observer and intra-
observer variation should be calculated aiming kappa scores above 0.5.
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Table 18 - Results of different methods of antigen retrieval for MLH1 antibody
METHOD OF ANTIGEN RETRIEVAL A2780 (+VE) CP70 (-VE)
None - -
Overnight incubation weak + -
0.05% saponin - -
0.1% trypsin - -
4x5 mins microwave in 200 mis citrate buffer * *
2x5 mins microwave in 200 mis citrate buffer * *
2x5 mins microwave in 750 mis citrate buffer - -
4x5 mins microwave in 750 mis citrate buffer +++ False ++
3x5 mins microwave in 750 mis citrate
buffer
+++
*= Sections 'cooked' off slide; ++ = moderate staining; +++ = good staining
Ovarian cancer cell lines; A2780 = MLH1 normal; CP70 = MLH1 defective
Table 19 - Results of different antibody dilutions
MLH1 Dilutions A2780 (+VE) CP70 (-VE)
1 in 10 +++ +++
1 in 20 +++ +++
1 in 50 +++ +
1 in 100 +++ -
1 in 200 ++ -
1 in 500 weak + -
PMS2 Dilutions A2780 (+VE) CP70 (-VE)
1 in 5 +++ +++
1 in 20 +++ +/-
1 in 50 Variable from weak + to +++ Intermittent +ve
1 in 100 Weak + -
1 in 200 Weak + -
MSH2 Dilutions A2780 (+VE) LOVO (-VE)
1 in 20 +++ +
1 in 50 +++ +/-
1 in 100 +++ -
1 in 200 + -
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1 in 50 +++ ++
1 in 100 +++ +
1 in 200 +++ -





1 in 20 ++++ ++++
1 in 50 - ++++
1 in 100 - ++++
1 in 200 - ++++
- = no staining; + = weak staining; ++ = moderate staining; +++ = good staining;
++++ = strong staining.
103
IB - IMMUNOHISTOCHEMISTRY- Immuno Reactive Score or Histoscore
The reporting of immunohistochemistry results has been a matter of controversy for
many years. Most work on this area has been done on oestrogen receptor (ER)
analysis in breast carcinoma, which is a known prognostic factor. Several authors in
the 1980s developed an 'immuno reactive score' (IRS) or 'histoscore' which is based
on a score for both intensity (I) and percentage of cells (%). However the mode of
calculation of differs markedly. Firstly, there is no agreement on the number of
categories for intensity to be used (0-3 or 0-4). Secondly, the percentage of positive
cells is sometimes on a subjective, often non-linear scale (0-3), whereas in others it is
the actual percentage, often rounded in decades, of cells positive for each intensity
category. Thirdly, the calculation of the final overall score varies from simple
addition (I + %) (Reiner, Neumeister et al. 1990), to multiplication (I x %) (Remmele,
Hildebrand et al. 1986), to complex formulae {EP,x(/+l)} (McCarty, Miller et al.
1985). Interestingly all of the above have been shown to be predictive for overall
survival of patients e.g. (Reiner, Neumeister et al. 1990) (additive), (Kieback, Press et
al. 1993) (multiplication), (Kinsel, Szabo et al. 1989) (complex).
The most commonly used 'H-score' gives a score from 0 to 300 and is calculated as
follows (McClelland, Finlay et al. 1990):
H-score = (% of cells stained at intensity category 1 x 1) + (% of cells stained at
intensity category 2x2) + (% of cells stained at intensity category 3 x
3)
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An early study on simple scoring systems by Remmele et al. ER detection by the gold
standard biochemical assay of dextran-coated charcoal (DCC) was compared to
immunohistochemistry (Remmele, Hildebrand et al. 1986). In 156 breast cancer
samples they found a closer correlation of biochemical and immunohistochemistry
scores using a histoscore than just the intensity or percentage scores alone. They also
commented on a closer correlation between DCC and the histoscore if it was
multiplied (I x %) compared to added (I + %); r=0.5947 and 0.5372 respectively.
However, they gave no p value or confidence intervals for this difference.
In another study of ER in breast cancer three methods of scoring
immunohistochemistry were compared: (1) an additive (I+%) quickscore; (2) a
multiplicative (Ix%) quickscore', and (3) the time consuming H-score (as detailed
above; range 0 to 300) (Detre, Jotti et al. 1995). In 96 tumours they found that the
quickscores (either additive or multiplicative) gave as good a correlation as the H-
score with the gold standard enzyme immunoassay (EIA), shown in table 20. They
also showed the quickscores were closely correlated to the H-score but importantly
took only approximately a quarter of the time to measure. They showed no advantage
between the additive and the multiplicative quickscore with the two being very
closely related (r=0.994). They also confirmed that the quickscore was reproducible,
with two independent observers in total agreement in 73% of cases. They suggested
the multiplication score might be preferred as it gives a wider range of results. The
major criticism of the multiplication histoscore is that it places a large reliance on the
intensity score, I, which is known to show intra- and inter-observer variation.
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Table 20 - Comparison of additive, multiplicative quickscore and histoscore
Detre et al
Compared to Spearman rank correlation
Score coefficient (r)
H-score EIA 0.843
I x % quickscore EIA 0.831
I + % quickscore EIA 0.832
I + % quickscore I x % quickscore 0.994
I x % quickscore H-score 0.892
I + % quickscore H-score 0.887
Ravn et al. examined the reproducibility of subjective categories for both the intensity
and percentage of cells staining for ER and PgR in 87 endometrial biopsies (both
stromal and epithelial cells) (Ravn, Rasmussen et al. 1993). For intensity no adequate
distinction between categories 1 and 2 could be made by subjective estimation (inter-
observer and intra-observer kappa scores <0.5). However strong staining (category 3)
or absence of staining (category 0) was reproducible (inter-observer and intra-
observer kappa scores >0.5). Kappa scores are explained in section 2B of results
chapter 4.
For percentage scoring they showed good agreement for the 0-10% and >90%
categories (inter-observer and intra-observer kappa >0.5). By contrast there was poor
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agreement (inter-observer and intra-observer kappa <0.5) for the 4 categories from
10-90% (i.e.10-25; 25-50; 50-75; 75-90%). By reducing the percentage categories (0-
10; 10-50; 50-90; >90%) to only four groups (0-3) they were able to produce a more
reproducible scoring system (inter-observer and intra-observer kappa >0.5). They
compared this 4 category, %-score to a time consuming absolute count of cells
(number stained/total number of cells) performed at high magnification with a
counting frame. For epithelial cells there was a good agreement between the two
systems (kappa 0.59) but not for stromal cells (kappa<0.5). Interestingly they showed
no advantage to a simplified H-score, based on (I x %)/3, compared to %-score (0 to
3) alone for correlation to the gold standard EIA measurement (r=0.659 and 0.674
respectively for ER). They did not compare intensity score with either the %-score or
El-score.
The Gynaecological Cancer Co-operative Group of the European Organisation for
Research and Treatment of Cancer (EORTC) published guidelines in 1997 on a
scoring system for immunohistochemical staining in basic research (van Diest, van
Dam et al. 1997). With regard to the histoscore system they commented that (1) the
percentage scores are only rough estimates without counting; (2) an intensity score
assigned to an individual nucleus is highly subjective and (3) there are many inter-
observer discrepancies in mid-range scores (van Diest, Weger et al. 1996). They
recommended the use of an interactive approach based on stereology that is quick,
simple, and reproducible (Polkowski, Meijer et al. 1996; Oudejans, Jiwa et al. 1997).
This approach applies a systematic random sampling tehnique for selection of a
defined number of fields of vision in which the positivity of cells is counted with a
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point grid. A few cells (2-4) are counted in a large number of fields (50-100).
However, the Polkowski study (Polkowski, Meijer et al. 1996) can be criticised as the
32 areas studied (from 25 cases of Barrett's oesophagus) were carefully pre-selected
and reproducibility studies were performed on only 8 areas. Similarly the study by
Oudejans on 80 cases of Hodgkin's disease does not give any reproducibility results
(Oudejans, Jiwa et al. 1997). This relatively new method of scoring has not yet been
applied to many studies in contrast to the histoscore method. It has yet to be accepted
as the gold standard. They do recommend that regardless of the system used, the
quantification method should be provided, in addition to the exact data.
Kappa scores
It is of concern that few studies of the biological significance of
immunohistochemistry produce inter and intra-observer agreement measurements.
Adams et al. recently reported on a comparison of a 4 point intensity scale (0-3) with
a descriptive scale which combined both the intensity and distribution of positive
staining (Adams, Green et al. 1999). In scoring 92 cervical tumours for p53 and
EGFR twice, 6 months apart, by three independent observers they showed a very low
value for the intra-observer variation with a mean weighted kappa of 0.32 (range 0.24
to 0.47). There was no large difference in inter-observer kappa variation between the
2 scoring systems with an overall mean weighted kappa score of 0.49 for the 4 point
intensity scale compared to an overall mean weighted kappa score of 0.48 for the
descriptive method. However, a marked improvement in weighted kappa was found
when the more widely varying scores were discussed by the panel of observers and a
consensus score agreed (k=0.63).
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The degree of staining of a slide is very subjective. Many different systems exist for
the scoring of immunohistochemical stains. Any system should be a) sensitive
enough to identify important differences and b) reproducible in time and between
different scorers. All scoring should be of the tumour cells alone and not of
surrounding normal tissue.
IB (I) - The %-score
Slides can be scored for the number of positive cells. The most frequently used
technique is to score the percentage of cells positive in decades i.e. 10%, 20%, 30%,
etc. This has the advantage of a linear scale but has the disadvantage of the difficulty
in the naked eye being able to tell differences of only 10%. The large interobserver
and intraobserver variation with this technique can result in any difference found
being spurious. To try to improve utility we opted for an easier percentage score that
we felt was obvious to the naked eye, shown in table 21. Our scale has the
disadvantage of loss of detail with a score of 2 and nonlinearity.
Table 21 - Percentage score of cells
SCORING % OF CELLS
0 less than 5% of cells positive
1 5 to 20% of cells positive
2 20 to 80% of cells positive
3 over 80% of cells positive
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This can be said in lay terms as follows,
0- very rare cells stain positive
1 - a few cells positive but most negative
2-moderate numbers of cells positive but noticeable amount still negative
3- most cells positive with very rare negative cells
IB (II) - The I-score
Intensity of staining is a reflection of the gene product. A cell with a large amount of
the protein of interest will turn a much darker brown compared to a cell with only a
few copies of the protein. Immunohistochemical detection of protein depends on the
sensitivity of the antibody. Any variability in the time each of the antibodies is left in
contact with the slide and any variability in the concentration of solutions will result
in a variation in intensity of the stain. Therefore to make any score for intensity
relies on having an internal positive and negative control for each run.
Table 22 - Scoring for intensity
SCORING FOR INTENSITY
0 no stain
1 weakly positive (+)
2 Positive (++)
3 strongly positive (+++)
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IB (III) - The IHC-score
The overall score for each slide was calculated by addition of the % and I score i.e. a
scale from 0 to 6 maximum. This had the advantage of including both types of
scoring but had the disadvantage of giving equal weight to both scores. Previous
scoring has included a multiplication of the decade % of cells by the intensity to score
to try to give a 'product' of the total amount of protein of interest on the slide.
IB (IV) - Sources ofvariation
Variability in the scoring can be due to a number of factors including; contamination
by normal cells; necrotic tumour cells; inter-scorer variability; intra-scorer variability;
variability in the staining technique. We have tried to allow for variability in the
staining technique by scoring 2 slides for each block of interest. To allow for
interobserver variability each slide has been scored independently by 2 observers. We
have included some repeat scores to measure intraobserver variability. All slides were
scored blinded to clinical outcome to avoid potential bias.
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1C - IMMUNOHISTOCHEMISTY- Ki67SCORING
Unlike the other primary antibodies being studied we decided to use image analysis
for scoring the Ki67 slides for 2 reasons, viz:
a) There appeared to be no variation in intensity over the slides. There was either a
strong brown stain in a cell or none.
b) Much previous work has been done on scoring for Ki67 using image analysis.
2 slides were scored for each block of interest using CAS 200® system. The
percentage of positive nuclear staining was calculated using the Quantitative
Proliferation Index® program. The tissue to be analyzed is stained so that non¬
specific nuclear proteins (and thus, morphologically, the entire nucleus) are stained
with haematoxylin; and specific nuclear proteins (e.g. Ki67) are immunostained with
diaminobenzidene (DAB). These two components of the cell nucleus can then be
sensed separately by the two image sensing channels of the CAS 200® camera at
620nm and 500nm respectively. All of the nuclei will be sensed at 620nm. However,
only the antigen antibody stain complex absorbs light at 500nm, since haematoxylin is
transparent at this wavelength. Stereological measurement principles are then used to
estimate the percentage, by volume, of antibody-tagged nuclei as a ratio of the total
volume of cell nuclei. On each image field a measurement is made of the total area of
the nuclei from the 620nm image, and the total area of the antibody-tagged nuclei in
the 500nm image. The latter divided by the former, expressed as a percentage, is the
proliferation index. Individual cells are not counted but to correct for this average
nuclear size and antibody size is estimated for each slide. For each slide the final
percentage score was the mean of at least 10 fields and at least 1,000 cells.
112
2 - VARIABILITY OF IMMUNOSCORES
2A - SOURCES OF VARIA TION
Variability may exist within the immunoscores for a number of reasons. The
principle variability we are trying to measure is the variability due to the expression of
the protein in question. However other sources of variation exist and may lead to bias
of the results. These include;
1) Variability due to the staining technique. This can be determined by staining the
same tissue section on multiple staining runs.
2) Variability due to the observer over time. This can be examined by scoring the
same slide on different occasions over time.
3) Variability betM>een observers. This can be investigated by 2 observers who
independently score the same slide. It is important that the 2 observers use the
same agreed scoring system.
4) Variability due to personal bias of the observer. Immunohistochemistry scoring
attempts to assign a score to a subjective assessment of browness and percentage
of cells staining. It is open to bias from preconceived ideas of the likely results by
the observers. To avoid bias from this, all slides should be scored blinded to
clinical outcome.
5) Variability ofprotein expression between tissues and within the same tissue.
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For MLH1, MSH2 and p53 scoring in order to reduce variability due to observers (3)
in this study we had two independent examiners; Dr M Mackean (MJM) and Dr. D
Millan (DM). DM is a consultant histopathologist specializing in gynaecological
malignancy. DM and MJM agreed a scoring system as previously described in the
materials and methods. DM provided training for MJM over a period of 4 months in
identifying ovarian tumour cells and the scoring system. All subsequent scoring
included in the results section was scored independently. Both scorers were blinded
to clinical outcome thus reducing variability due to beliefs of the observers (4). We
have called this the inter-observer variation.
To reduce variability due to the staining technique (1) both the examiners scored two
separate slides per tissue. These slides were stained on different runs at least 24 hours
apart. As two slides from the same tissue were scored at different examinations the
variability in those scores included both variability due to time (2) and due to staining
technique (1). We have called this the intra-slide variation.
MJM scored 46 slides a second time after 6 months from the first scoring blinded to
the first scores. This assessed the degree of variability over time (2). We have called
this the intra-observer variation.
Variability of tissue expression was examined in multiple blocks taken at the same
operation described in results section lc. We have called this the intra-block
variation.
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2A (I) - Reporting ofvariability
There are a number of methods used to examine the variability of scoring systems.
The most accurate statistical method which gives a weighting to the difference in the
score (e.g. a difference of 2 affects the score more heavily than a difference of 1) is to
use the kappa score. However in the literature an often reported method is to give the
percentage of times the score varied, and by how much, between the 2 scores. The
results below are reported in both formats for completeness. The use of a correlation
coefficient between scores, as is sometimes used, is inappropriate because it does not
take into account the degree of agreement by chance alone.
2A (II) - The principle ofa kappa statistic
Part of an observed agreement between different observers is due to pure chance. We
are interested in the agreement between observers above that of a pair of dice. The
kappa statistic is the observed agreement, corrected for chance, as a fraction of the
maximum agreement also corrected for chance (Svanholm, Starklint et al. 1989).
k = Pobs - Pchance
1 - Pchance
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2B - KAPPA SCORING OF VARIABILITY
Kappa scores were calculated for MLH1, MSH2, and p53. For each block of tissue
there were 4 scores for each protein (MLH1, MSH2, p53) for both intensity and
percentage score. This consisted of 2 slides scored by 2 observers i.e.
a) Slide 1 - score by MJM
b) Slide 1 - score by DM
c) Slide 2 - score by MJM
d) Slide 2 - score by DM
Each of these scores was based on a scale of 0 to 3. The weighted kappa results for
these scores give a heavier weighting the greater the difference in score. The intra-
slide kappa score was examined by comparing the score for (a) with the score for (c)
and also the score for (b) with the score for (d). The inter-observer kappa score was
examined by comparing the score for (a) with the score for (b) and also the score for
(c) with the score for (d). We have included all the scores for all blocks for the
calculation of the kappa scores. A guide to interpretation of kappa scores is given in
table 43. The results for MLH1, MSH2 and p53 are shown in tables 24 to 26.
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2B (I) - Guidelines for interpretation ofkappa values





0.81 - 1.00 Almost perfect
Table 23 - Guidelines for interpretation of kappa values
A kappa result of 0.00 means any agreement may be explained by chance alone. A
kappa result of 1.00 means complete agreement. A cut-off of 0.5 is often used as the
lower level of an acceptable agreement corrected for chance.
2B (II) - Ki67Kappa score
For Ki67 a different scoring system was used (see materials and methods for CAS
scoring system). Only one observer generated Ki67 scores, (MJM), due to the time
consuming nature of performing CAS scoring. 2 slides were again stained per block
of tissue and scored on different occasions (n=59). The intra-class correlation
coefficient was calculated at 0.789 (standard error = 0.053) as a measure of variability
and is similar to the intra-slide kappa score.
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Slide 1 I-DM * Slide 1 I-MJM
0.612 0.065 105
Slide 2 I-DM * Slide 2 I-MJM 0.698 0.066 104
Slide 1 %-DM * Slide 1 %-MJM 0.587 0.112 105
Slide 2 %-DM * Slide 2 %-MJM 0.755 0.067 104
Overall intensity 0.653 0.046 209
Overall percentage 0.711 0.057 209
MSH2 Intra-slide
Slide 1 I-MJM * Slide 2 I-MJM 0.604 0.072 106
Slide 1 I-DM * Slide 2 I-DM 0.590 0.069 105
Slide 1 %-MJM * Slide 2 %-MJM 0.610 0.078 106
Slide 1 %-DM * Slide 2 %-DM 0.603 0.085 105
Overall intensity 0.602 0.050 211
Overall percentage 0.607 0.057 211
MSH2 Intra-observer
Overall intensity 0.733 0.072 46
Overall percentage 0.692 0.087 46
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Slide 1 I-DM * Slide 1 I-MJM 0.731 0.043 104
Slide 2 I-DM * Slide 2 I-MJM 0.525 0.08 106
Slide 1 %-DM * Slide 1 %-MJM 0.688 0.065 104
Slide 2 %-DM * Slide 2 %-MJM 0.524 0.087 106
Overall intensity 0.685 0.038 210
Overall percentage 0.629 0.053 210
MLH1 Intra-slide
Slide 1 I-MJM * Slide 2 I-MJM 0.606 0.066 106
Slide 1 I-DM * Slide 2 I-DM 0.557 0.071 104
Slide 1 %-MJM * Slide 2 %-MJM 0.648 0.069 106
Slide 1 %-DM * Slide 2 %-DM 0.645 0.070 104
Overall intensity 0.583 0.048 210
Overall percentage 0.647 0.049 210
MLH1 Intra-observer
Overall intensity 0.689 0.096 46
Overall percentage 0.646 0.099 46
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Slide 1 I-DM * Slide 1 I-MJM 0.800 0.042 106
Slide 2 I-DM * Slide 2 I-MJM 0.820 0.036 105
Slide 1 %-DM * Slide 1 %-MJM 0.762 0.058 106
Slide 2 %-DM * Slide 2 %-MJM 0.780 0.048 105
Overall intensity 0.812 0.027 211
Overall percentage 0.773 0.037 211
p53 Intra-slide
Slide 1 I-MJM * Slide 2 I-MJM 0.902 0.019 105
Slide 1 I-DM * Slide 2 I-DM 0.910 0.024 107
Slide 1 %-MJM * Slide 2 %-MJM 0.735 0.067 105
Slide 1 %-DM * Slide 2 %-DM 0.739 0.055 107
Overall intensity 0.905 0.015 212
Overall percentage 0.737 0.04378 212
p53 Intra-observer
Overall intensity 0.851 0.044 46
Overall percentage 0.818 0.080 46
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2B (III) - Conclusions from kappa scores
Overall results are shown in table 27. The p53 scores were consistently the most
reproducible. There was no significant difference between DM and MJM for intra-
slide variability. The only kappa score less than 0.6 was for intra-slide variation of
MLH1 intensity (0.583). This suggests that most variation was seen for staining
technique for MLH1. However the overall intra-slide kappa scores compare
favourably to a small study of 22 endometrial tissue biopsies stained for oestrogen
(ER) and progesterone receptors (PgR) on two separate slides on separate occasions.
Ravn et al. showed an intra-slide kappa score for either intensity (scale 0 to 3) or
percentage (0 to 3) of 0.695 for ER and 0.600 for PgR (Ravn, Rasmussen et al. 1993).
For intra-slide variation the p53 intensity score was significantly more reproducible
than any other score with a kappa value of 0.905 (p<0.05 compared to p53 percentage
kappa score). For both intra-observer and inter-observer kappa scores there was no
significant difference seen between the percentage and intensity scores in
reproducibility. The intra and inter-observer kappa scores compare very favourably to
a detailed study of variation between 3 observers over time by Adams et al. (Adams,
Green et al. 1999). For p53 and EGFR, using a 0-3 scale for intensity scoring, they
showed intra- and inter-observer kappa scores of 0.32 and 0.49 respectively.
We have, therefore, shown remarkable reproducibility of the scoring system between
2 independent observers and between 2 slides of the same tissue and on 2 different
occasions for MLH1, MSH2 and p53.
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Table 27 - Overall Kappa values
INTER-
OBSERVER
WEIGHTED KAPPA STANDARD ERROR N=
MSH2 Intensity 0.653 0.046 209
MSH2 Percentage 0.711 0.057 209
MLH1 Intensity 0.685 0.038 210
MLH1 Percentage 0.629 0.053 210
P53 Intensity 0.812 0.027 211
P53 Percentage 0.773 0.037 211
INTRA-SLIDE WEIGHTED KAPPA STANDARD ERROR N=
MSH2 Intensity 0.602 0.050 211
MSH2 Percentage 0.607 0.057 211
MLH1 Intensity 0.583 0.048 210
MLH1 Percentage 0.647 0.049 210
P53 Intensity 0.905 0.015 212
P53 Percentage 0.737 0.043 212
Ki67 Percentage 0.789 0.053 59
INTRA-
OBSERVER
WEIGHTED KAPPA STANDARD ERROR N=
MSH2 Intensity 0.733 0.072 46
MSH2 Percentage 0.692 0.087 46
MLH1 Intensity 0.689 0.096 46
MLH1 Percentage 0.646 0.099 46
P53 Intensity 0.851 0.044 46
P53 Percentage 0.818 0.080 46
2C - PERCENTAGESCORING OF VARIABILITY
This method examines the difference between the 2 scores and the number of times
the scores vary by these differences. As our scoring scale is from 0 to 3 the difference
between the scores can vary from a minimum of 0 to a maximum of 3. This is then
expressed as a percentage of the total number of slides scored.
2C (I) - Intra-observer variation over time
The results are shown in the table 28 and figure 22. The scores were the same for the
same slide scored for a second time after 6 months in over 70% of the 46 slides
examined. This compares favourably with a study of intra-observer variation in ER
scoring using a similar 0-3 scale for both intensity and percentage staining. On 50
breast cancer specimens Remmele et al. showed an agreement of 78% for intensity
and 86% for percentage score (Remmele, Hildebrand et al. 1986). In the current study
there was no significant difference between the three antibodies examined. On only 2
occasions out of a possible 276 (6x46) did the score vary by 2 and never by 3.
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Table 28 - Intra-observer variation over time
INTRA-OBSERVER VARIATION OVER TIME (N=46)
Difference
in scores
I-MSH2 %-MSH2 I-p53 %-p53 I-MLH1 %-MLHl
0 35 38 35 38 34 35
76% 83% 76% 83% 74% 76%
1 11 8 11 7 11 11
24% 17% 24% 15% 24% 24%
2 0 0 0 1 1 0
0% 0% 0% 2% 2% 0%
3 0 0 0 0 0 0
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2C (II) - Intra-slide variation
Results are shown in the table 29 and figure 23 below. p53 scores were more
consistently in agreement than those for MSH2 and MLH1 with 70% and 82% of
scores the same for percentage and intensity of p53 respectively. The worst
concordance was for intensity ofMLH1 with only 59% of scores remaining the same.
There were very few scores varying by 2 or 3. Interestingly a significant number of
these were for percentage score of p53 suggesting when there is a variation in p53 %-
score this tends to be of a larger scale.
Table 29 - Intra-slide variation
INTRA-SLIDE VARIATION (N= MAX. 212)
Difference
in scores
I-MSH2 %-MSH2 I-p53 %-p53 I-MLH1 %-MLHl
0 138 138 174 148 124 140
66% 66% 82% 70% 59% 66%
1 70 66 38 51 83 67
33% 31% 18% 24% 39% 32%
2 3 7 0 11 5 5
1% 3% 0% 5% 2% 2%
3 0 0 0 2 0 0
0% 0% 0% 1% 0% 0%
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2C (III) - Inter-observer variation
The results are shown in the table 30 and figure 24. The overall agreement in scores
is slightly lower at around two thirds for all the antibodies. The MLH1 scores show
slightly more variation than the other antibodies. Again the number of variations of 2
or 3 are very small. These compare favourably to the results by Remmele et al 1986
for ER immunohistochemistry on a similar 0-3 scale (Remmele, Hildebrand et al.
1986). Between experienced observers they showed absolute agreement in 58 and
60% for intensity and 78 and 82% for percentage scores.
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Table 30 - Inter-observer variation in scores
INTER-OBSERVER VARIATION (N= MAX. 211)
Difference
in scores
I-MSH2 %-MSH2 I-p53 %-p53 I-MLH1 %-MLHl
0 145 159 153 147 131 139
69% 76% 72% 70% 63% 67%
1 62 44 52 54 74 62
30% 21% 25% 25.5% 36% 30%
2 2 4 6 9 3 7
1% 2% 3% 4% 1% 3%
3 0 2 0 1 0 0
0% 1% 0% 0.5% 0% 0%
Inter-observer variation in scores
l-msh2 %-msh2 l-p53 %-p53 l-mlh1 %-mlh1
Difference in score
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2D - VARIABILITYOFIMMUNOSCORES - CONCLUSIONS
• This is the first study to examine reliability of scoring for MLH1 and MSH2
immunohistochemistry in any detail and shows remarkable reproducibility of the
scoring system between 2 independent observers and between 2 slides of the same
tissue and on 2 different occasions.
• Only intensity of MLH1 score fell below a kappa score of 0.6 (0.583) for intra-
slide variability i.e. between IHC runs on separate days.
• Scoring for p53 was found to be the most reliable between scorers, over time and
over different IHC runs.
• Testing of Ki67 scoring for reliability was limited due to the time consuming
nature of CAS scoring but was found to be good (0.789) between IHC runs on
separate days (intra-slide).
• Percentage scoring of reliability is often quoted in the literature instead of kappa
scores. Using percentage scoring of reliability we confirmed our above findings
and these compared favourably to other IHC scoring used routinely.
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Chapter 6 - IMMUNOHISTOCHEMISTRY
A - RESULTS OF IMMUNOSCORES AND EXAMPLES
A - (i) PICTURES OF IMMUNOHISTOCHEMISTRY
Pictures of typical immunohistochemistry are shown in the following pages. These
are shown at x50 magnification. The index for the pictures is as follows;
Picture 1 - MLH1 staining score 3+3 ovarian tumour
Picture 2 - MLH1 staining score 2+2, ovarian tumour
Picture 3 - MLH1 staining score 1 + 1, ovarian tumour
Picture 4 - MLH1 staining score 3+3, ovarian tumour
Picture 5 - MSH2 staining score 1+1, ovarian tumour
Picture 6 - MSH2 staining score 2+2, ovarian tumour
Picture 7 - MSH2 staining score 3+3, ovarian tumour
Picture 8 - p53 staining score 1+1, ovarian tumour
Picture 9 - p53 staining score 2+2, ovarian tumour
Picture 10 - p53 staining score 3+3, ovarian tumour
Picture 11 - Ki67 staining, low, ovarian tumour
Picture 12 - Ki67 staining, high, ovarian tumour
Picture 13 - Control slide, ovarian cell line A2780, +ve for MLH1
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Picture 14 - Control cell line A2780, +ve for MSH2
Picture 15 - Control slide, ovarian cell line CP70, -ve for MLH1
Picture 16 - Control slide, colon cancer cell line LOVO 1, -ve for MSH2
Picture 17 - Normal colon, Crypts of Lieberkuhn, +ve for MLH1
Picture 18 - Normal colon, Crypts of Lieberkuhn, +ve for Ki67
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Picture 1 - ML!II staining score 3+3 ovarian tumour
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Picture 2 - MLH1 staining score 2+2, ovarian tumour
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Picture 3 - MLH1 staining score 1+1, ovarian tumour
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Picture 4 - MLH1 staining score 3+3. ovarian tumour
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Picture 5 - MSH2 staining score 1 + 1. ovarian tumour
Picture 6 - MSH2 staining score 2+2, ovarian tumour
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Picture 7 - MSI 12 staining score 3+3, ovarian tumour
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Picture 8 - p53 staining score 1 + 1, ovarian tumour
,> "• »• ^ t, ;
,s- >;
'f # ^ + \¥
, * P •• "/ - i , _ »
' ^ V, n,
If.'1. •••. -v -/ f*i\
■'5 '" *. ' mSr* •''1r ■ - - *. v • •"■ f
1





Picture 9 - p53 staining score 2+2, ovarian tumour
Picture 10 - p53 staining score 3+3, ovarian tumour
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Picture 11 - Ki67 staining, low, ovarian tumour
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Picture 12 - Ki67 staining, high, ovarian tumour
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Picture 14 - Control cell line A2780, +ve for MSH2
144
Picture 15 - Control slide, ovarian cell line CP70. -ve for ML1I1
« 1
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Picture 16 - Control slide, colon cancer cell line LOVO 1, -ve lor MSH2
Picture 17 - Normal colon, Crypts of Lieberkuhn. +ve lor ML111
Picture 18 - Normal colon. Crypts of Lieberkuhn. +ve for Ki67
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A - (ii) DISTRIBUTION OFIMMUNOSCORES (N=97)
The statistics of the immunoscores are shown in the table 31. Scores were not
normally distributed with an excess of high scores for I-MSH2, %-p53, %-MLHl and
%-MSH2. This is shown in the histograms (figure 2, 3 and 4). This means for the
intensity scores only about one third of scores were below the middle value of 1.5
(21%, 32% and 34% for MSH2, MLH1 and p53 respectively). For percentage scores
this was more striking with 12%, 14% and 26% below the middle value of 1.5 for
MSH2, MLH1 andp53 respectively.
Table 31 - Statistics of all immunoscores (n=97)
I-MSH2 %-MSH2 %-KI67 I-P53 %-P53 I-MLH1 %-MLH1
Count 97 97 95 97 97 97 97
Mean 2.007 2.354 16.403 2.075 2.178 1.888 2.269
Median 2 2.5 15 2.5 2.625 2 2.5
SD 0.6034 0.7302 11.5281 0.9828 0.9859 0.6544 0.6609
95%CI 0.1201 0.1453 2.3181 0.1955 0.1962 0.1302 0.1315
1st quartile 1.75 2 6.25 1 1.75 1.5 2
3rd quartile 2.5 3 24 3 3 2.375 2.75
Min. 0 0 0.5 0 0 0 0
Max. 3 3 47 3 3 3 3
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Figure 2 - Histogram of % Ki67 scores, N=95. This shows a skewed distribution



















Figure 3 - Histogram of % scores for MLH1, p53 and MSH2, N=97. This shows a
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Figure 4 - Histogram of intensity scores for MLH1, p53 and MSH2, N=97. This
shows a skewed distribution of higher scores.
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A (iii) - COMPARISON WITH OTHER STUDIES
We were expecting the number of negative (i.e. 0 stain) cases for mismatch repair
proteins to be of the order of 10 to 17% from the literature on microsatellite analysis
(see introduction). Interesingly we only found 7 out of 97 blocks to be totally
negative for MLH1 and/or MSH2 (7.2%). There has only been one other study of
immunohistochemistry for DNA mismatch repair proteins in ovarian cancer (Samimi,
Fink et al. 2000). They do not quote the statistics of their immunoscores but from the
histogram of the results (figure 2 in the paper) it appears they found similar results. A
comparison of the percentage scores between the 2 studies is shon in table 32 below.
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Table 32 - Comparison of the distribution of percentage staining scores between this
study and Samimi study.
PERCENTAGE
SCORE
0 1 2 3
This study
MLH1 (n=97)
2.1% 4.1% 29.9% 63.9%
Samimi study
MLH1 (n=62)
3.3% 6.6% 39.3% 50.8%
This study
MSH2
5.2% 2.1% 22.7% 70.1%
Samimi study
MSH2
1.6% 3.2% 32.3% 62.9%
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B - HETEROGENEITY OF STAINING BETWEEN AND WITHIN TISSUES
i.e. INTRABLOCK VARIATION (RESULTS FROM REPEAT BLOCKS)
(N=13)
Tissue removed at operation and sent to the pathology laboratory is often from more
than one organ e.g. ovary, omentum, uterus. For each of these organs multiple blocks
are cut from representative areas e.g. tumour, normal looking tissue, resection
margins. Therefore from any one operation multiple blocks are obtained from
different tissues and within the same tissue. These are embedded in paraffin for later
sectioning and examination under light microscopy. Blocks consist of approximately
lcm3 of tissue.
In this study we managed to obtain more than one block from the same operation in
only 13 patients, in 6 patients the 2 blocks were from different tissue. In the
remaining 7 the blocks were taken from the same tissue. These pairs were scored as
before and the scorers were unaware of the pairing of various slides. Despite the
small number we were interested to examine the variability of the scores given for
these 13 pairs. Results are shown in table 33. The variability consists of the sum
from; (1) variability of staining; (2) variability of scoring; (3) variability of protein
expression within the same tissue (n=7) and (4) variability of protein expression from
different tissues (n=6). The variability from (1) and (2) is examined and described
under the kappa scores (results section 2). Therefore these results can be used to give
some idea of the variability due to different protein expression in and within tissues.
The numbers are too small to perform kappa scoring but we saw a surprisingly small
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mean difference of less than 0.5 for MSH2, MLH1 and p53 expression. The
difference with Ki67 was more striking with a mean difference of 6.46 and range of 1
to 17 difference in %-scores. On paired 2-tailed t-test the difference in I-MSH2 was
found to reach significance (p=0.017). However, this significance was lost if same
tissue or different tissues were considered. The individual results for the 13 patients
are shown in figures 5-7. The results suggest that there is some but not a significant
amount of variability between and within tissues of the IHC staining. The small
number of samples examined may have missed smaller amounts of variability but our
results suggest this is less than 0.5 of a score. For the purpose of the main study the
mean of the two scores was taken.
Table 33 - Statistics of the difference in scores between 2 blocks taken at the same










Mean 6.46 0.37 0.42 0.38 0.37 0.19 0.35
Paired 2-tailed
t-test (p value)
0.86 0.017 0.15 1.00 0.5 0.087 0.19
Range 1-17 0-1 0-1.25 0-1.75 0-1 0-0.75 0-1.75
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Difference in intensity scores on repeat blocks (n=13)
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Figure 5 - Difference in intensity scores on repeat blocks (n=13)
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Figure 6 - Difference in percentage score on repeat blocks
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Figure 7 - Difference in % Ki67 scores on repeat blocks
C - CORRELATION BETWEEN IMMUNOSCORES
The concept of scoring for both intensity of stain (I-score) and percentage of cells
positive (%-score) has been accepted over the years. We examined the correlation
between the % and I-scores by Spearman Rank correlation coefficients. We found a
close correlation with % and I of p53 and also % and I of MLH1 (r=0.88 and 0.78;
p<0.001 respectively). For I and % of MSH2 the correlation was less close but still
significant (r=0.50; p<0.001). This is shown in figure 8.
We also found a positive association between the expression of the two MMR
proteins studied with a weak positive correlation between MLH1 and MSH2 %-scores
(r=0.30; p=0.022). This is shown in figure 9.
Because of the previous finding of increased expression of MMR proteins in
proliferating cells (Wilson, Ewel et al. 1995; Leach, Polyak et al. 1996) the
association of MMR, p53 and Ki67 pre-chemotherapy immunoscores was studied by
Spearman rank correlation coefficients. The results are shown in table 34. Ki67
scores showed a positive correlation with both I- and %-score for MLH1 and MSH2
%-score (r= 0.39; 0.46 and 0.44; p= 0.002; <0.001 and 0.001 respectively) but not p53
scores. This is shown in figure 10. This confirms increasing expression of MMR
proteins with increasing proliferation.
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Table 34 - Spearman rank correlation coefficients between immunoscores. N=97






















































































• Spearmank Rank correlation coefficients (r) shown above
• p values shown below in italics
• Significant (p<0.05) values shown in bold
• NA = not applicable (scores are derived from each other)
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Figure 8 - Correlation of intensity and percentage scores
Correlation of I-MSH2 and %-MSH2
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Correlation of I-MLH1 and %-MLH1
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Figure 9 - Correlation between Mismatch Repair prechemotherapy immunoscores
Correlation of I-MSH2 and I-MLH1
prechemotherapy immunoscores r= 0.24;
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Figure 10 - Correlation ofMMR protein expression and Ki67
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D - CONCLUSIONS OF IMMUNOSCORES
• Adequate positive and negative controls for IHC were obtained only 3/4 of the
time.
• Only IHC runs with concurrent adequate controls were used for scoring.
• The distribution of MSH2, and MLH1 scores are skewed with more scores at the
top of the range than the lower (0-3 range).
• The distribution of p53 was bimodal with two peaks at 0 and 3 scoring.
• Only 7% of blocks were negative for MSH2 and/or MLH1 (i.e. mismatch repair
deficient).
• The distribution of Ki67 scores are skewed to the lower range with a tail of higher
scores.
• There is some heterogeneity of IHC staining between and within tissues but this
was not found to be significant on a limited study and was less than 0.5 of a score
for MLH1, MSH2 and p53.
• Intensity and percentage scores appear related to one another for MLH1, p53 and
MSH2. This suggests there is some coregulation of expression of these proteins
both within a single cell and between surrounding cells.
• I-MLH1, %-MLHl and %-MSH2 scores showed a significant association with
Ki67 score. This suggests expression of these MMR proteins is related to
proliferation.
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• There is a weak association of%-MLHl and %-MSH2 suggesting coregulation of
expression.
• There appears to be no correlation between mismatch repair protein expression
and p53 expression.
Chapter 7 - CORRELATION OF
IMMUNQSCORES WITH CLINICAL
FEATURES AND OUTCOME
A - CORRELATION OF IMMUNOSCORES WITH STAGE, RESIDUAL
DISEASE AND PERFORMANCE STATUS
Because of the known prognostic significance of stage, residual disease, histology and
performance status (Voest, van Houwelingen et al. 1989) we examined the
relationship of these variables with the proteins studied. These were examined by
Kruskal-Wallis one-way analysis of variance. The results are shown in table 35 and
figure 11. There was a statistically significant association with stage of the tumour
and %-scores for MLH1, MSH2 and Ki67 (p=0.0092, 0.0049 and 0.0054
respectively), and MSH2 I-score (p=0.019). The MLH1 I-score approached
significance with stage (p=0.062). This suggests there is increased proliferation and
also increased expression of MMR proteins with advanced stage (3 or 4). Scores for
p53 did not show any association with stage. All immunoscores showed no
association with performance status or residual disease.
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Table 35 - Association of immunoscores with clinical prognostic factors in ovarian
cancer
Each cell shows the median value and the interquartile range in brackets. Significant
values (p<0.05) are shown in bold.
STAGE
Ic/II (n=15) III/IV (n=43) p-value
I-MLH1 1.50 (1.00-2.25) 2.00 (1.50-2.50) 0.062
%-MLHl 2.00 (1.63-2.28) 2.50 (2.00-2.75) 0.0092
I-MSH2 1.75 (1.25-2.13) 2.25 (1.81-2.28) 0.019
%-MSH2 2.00 (1.56-2.50) 2.75 (2.25-3.00) 0.0049
I-p53 2.00 (1.38-2.81) 2.67 (1.00-3.00) 0.51
%-p53 2.25 (1.00-3.00) 2.75 (1.75-3.00) 0.35
%-Ki67 9(4-15) 17(8.13-26) 0.0054
PERFORMANCE STATUS
0(n=19) 1 or 2 (n=39) p-value
I-MLH1 1.75 (1.29-2.25) 1.75 (1.46-2.44) 0.86
%-MLHl 2.25 (2.00-2.63) 2.25 (2.00-2.75) 0.86
I-MSH2 1.92(1.75-2.25) 2.25 (1.69-2.28) 0.19
%-MSH2 2.25 (2.00-2.75) 2.50 (2.19-3.00) 0.23
I-p53 2.00 (1.50-3.00) 2.67 (1.00-3.00) 0.98
%-p53 2.50 (1.69-3.00) 2.67(1.63-3.00) 0.95
%-Ki67 13 (4-17) 16(8-26) 0.16
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RESIDUAL DISEASE
<2cm (n=20) >2cm (n=38) p-value
I-MLH1 2.00 (1.25-2.31) 1.75 (1.50-2.34) 0.97
%-MLHl 2.25 (2.00-2.56) 2.38 (2.00-2.75) 0.77
I-MSH2 2.13 (1.75-2.31) 2.00(1.66-2.25) 0.89
%-MSH2 2.38 (1.72-2.81) 2.50 (2.16-2.84) 0.4
I-p53 2.50 (1.63-3.00) 2.50 (1.00-3.00) 0.54
%-p53 2.63 (1.25-3.00) 2.38 (1.75-3.00) 0.72
%-Ki67 16(5-21) 15 (7-25) 0.65
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Figure 11- Early stage is associated with lower %-MLHl, MSH2, Ki67 and I-MLH1
immunoscore
Shown by Box plot: Line inside box = median, Box = inter-quartile range, Error bars












































B - CORRELATION OF IMMUNOSCORES WITH HISTOLOGY
Because of the previous finding of a correlation of MSI and endometrioid histology
(Fujita, Enomoto et al. 1995; King, Carcangiu et al. 1995), we investigated any
possible correlation of immunoscores with histology using Kruskal-Wallis one-way
analysis of variance. There was a significant correlation with MMR protein
expression and histology (see table 36 and figure 12). Only 3 histologies (not
including endometrioid) were included in the analysis due to the small number of
patients with other histological types. For MLH1 there was a higher median %- and I-
score for the papillary type compared with serous cystadenocarcinoma or
adenocarcinoma (p=0.0076 and 0.038 respectively; n=49). For MSH2 a higher
median I-score was seen with both serous cystadenocarcinoma and papillary
adenocarcinoma compared to adenocarcinoma (p=0.023; n=49). This suggests a
consistently lower expression of MMR proteins in the adenocarcinoma histological
subtype.
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Table 36 - Association of histology with immunoscores







N= 18 16 20
I-MLH1 1.75 (1.25-2.25) 1.75 (1.00-2.00) 2.25 (1.63-2.50) 0.038
%-MLHl 2.00 (1.75-2.50) 2.00 (1.75-2.00) 2.50 (2.30-3.00) 0.0076
I-MSH2 2.25 (2.00-2.50) 1.75 (1.25-2.00) 2.25 (1.88-2.25) 0.023
%-MSH2 2.67 (2.25-3.00) 2.25 (2.00-2.88) 2.50 (2.25-3.00) 0.58
I-p53 2.88 (2.00-3.00) 2.00 (1.00-3.00) 2.75 (1.00-3.00) 0.85
%-p53 2.83 (2.00-3.00) 2.00 (2.00-3.00) 2.75 (1.75-3.00) 0.60
%-Ki67 10(6-16) 16(6-27) 19(9-28) 0.088
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Figure 12 - Correlation of immunoscores with histology
Shown by Box plot: Line inside box = median, Box = inter-quartile range, Error bars






C - CORRELATION OF IMMUNOSCORES WITH SURVIVAL
All patients had a histological diagnosis of ovarian adenocarcinoma and were treated
with primary cisplatin combination chemotherapy. The median overall survival of the
patients is 29 months. A Cox proportional hazards model, stratified for type of
chemotherapy, was used to determine whether immunohistochemistry results for
MMR, p53 or Ki67 were correlated with survival. Results are shown in table 37.
On univariate analysis both early stage (IC or II) and residual disease <2cm were
good prognostic features (Hazard Ratio (HR)=2.66; 95%CI=1.14-6.19; p=0.014 and
HR=2.47; 95%CI=T. 15-5.31; p=0.014 respectively). The Kaplan-Meier survival
curves for stage and residual disease are shown in figures 13 + 14. On univariate
analysis only the MSH2 %-score was significant (HR=1.66; 95%CI=1.02-2.72;
p=0.042) with an increased percentage of cells expressing MSH2 correlating with
poor survival. However this association was absent on multivariate analysis and
review of the data suggested that the significance of the MSH2 %-score on univariate
analysis was due to the association between high % MSH2 expression and late stage,
which is itself a poor prognostic feature.
Multivariate analysis for survival, stratified for chemotherapy regimen, and using a
model including established prognostic factors of stage, extent of residual disease and
performance status was performed for each of the immunohistochemistry scores. Of
the immunoscores only the MLH1 I-score was statistically significant (HR=0.46;
95%CI=0.22-0.94; p=0.031). This implies that after correcting for clinical prognostic
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features, a low intensity of staining for MLH1 pre-chemotherapy is an independent
predictor of poor overall survival. Kaplan-Meier survival curves showing the patient
population separated by both MLH1 I-score and stage are shown in figure 15.








Stage 3.02 1.30 - 7.00
Residual
Disease




I-MLH1 0.76 0.42-1.39 0.46 0.22 - 0.94
%-MLHl 1.00 0.56-1.78 0.71 0.38-1.33
I-MSH2 0.93 0.54- 1.60 0.69 0.39-1.22
%-MSH2 1.66 1.02-2.72 1.28 0.72-2.27
I-p53 0.88 0.63 - 1.23 0.78 0.56-1.11
%-p53 0.94 0.68 - 1.31 0.78 0.54-1.12
%-Ki67 1.03 0.99-1.07 1.03 0.98-1.07
*Multiplicative change in hazard for a unit increase in the corresponding variable
Significant values shown in bold
175
Figure 13 - Kaplan Meier Curve of cause specific survival stratified for residual
disease (n=58)
Time (years)
Figure 14 - Kaplan Meier Curve of cause specific survival stratified for stage (n=58)
Time (years)
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Loss ofMismatch Repair Expression and survival
As a reduction in either MLH1 or MSH2 could lead to loss of function of DNA
mismatch repair we compared 2 groups of patients for survival. Those with intact
mismatch repair (defined as intensity score for both MLH1 and MSH2 of over 1.5)
and those with Toss of I-MMR' (i.e. I-MLH1 <=1.5 and/or I-MSH2 <= 1.5). We
used intensity scores as these were the most significant in the above analysis.
Interestingly adding in those patients with a low intensity of MSH2 as well as low I-
MLH1 identified more accurately a subgroup of poor prognosis patients than I-MLH1
alone, shown in table 38. If a patient has either a reduction in I-MLH1 and/or I-
MSH2 they are 3.64 times more likely to die based on a Cox multivariate analysis
(including stage, residual disease and performance status; stratified for chemotherapy)
compared to patients with intact MMR. The median survival for patients with Toss of
I-MMR' is 21 months (647.5 days) compared to 39 months (1201 days) for intact I-
MMR, shown in figure 16.
Table 38 - Univariate and multivariate analysis for survival and loss ofMMR status











3.64 1.66 - 7.99
p=0.0012
*Loss of I-MMR is defined as I-MLH1<= 1.5 and/or I-MSH2 <=1.5
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D - CORRELATION OF IMMUNOSCORES WITH TIME TO
PROGRESSION
The median time to progression (TTP) for these patients was 18 months. A Cox
proportional hazards model, stratified for type of chemotherapy, was used to examine
whether immunohistochemistry results for MMR, p53 or Ki67 were correlated with
time to progression. Results are shown in table 39.
On univariate analysis both early stage (i.e. stage 1C or II) and residual disease <2cm
were good prognostic features (HR=2.25; 95%CI=1.05-4.84; p=0.027 and HR=2.63;
95%CI=1.31-5.31; p=0.004 respectively). On univariate analysis only the MSH2 %-
score was significant (HR=1.67; 95%CI=1.02-2.73; p=0.024). This means patients
with an increased percentage of cells expressing MSH2 showed a shorter time to
progression.
On multivariate analysis using a model including established prognostic factors of
stage, extent of residual disease and performance status, none of the prechemotherapy
immunoscores predicted for TTP, again suggesting that the significance of the MSH2
%-score on univariate analysis was due to its association with stage.
Again, as a reduction in either MLH1 or MSH2 could lead to loss of function ofDNA
mismatch repair, we compared 2 groups of patients for time to progression. Those
with intact mismatch repair (defined as intensity score for both MLH1 and MSH2 of
over 1.5) and those with Toss of I-MMR' (i.e. I-MLH1 <=1.5 and/or I-MSH2 <= 1.5).
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We used intensity scores as these were the most significant for survival. Interestingly
adding in those patients with a low intensity of MSH2 as well as low I-MLH1
identified a subgroup of poor prognosis patients. If a patient has either a reduction in
I-MLH1 and/or I-MSH2 they are 2.37 times more likely to have disease progression
based on a Cox multivariate analysis (including stage, residual disease and
performance status; stratified for chemotherapy) compared to patients with intact
MMR. Shown in figure 17.




Hazard Ratio* 95% CI Hazard Ratio* 95% CI
Stage 2.25 1.04 - 4.84
Residual
Disease




I-MLH1 0.89 0.52-1.52 0.65 0.35 - 1.19
%-MLHl 1.08 0.63 - 1.86 0.86 0.48 - 1.54
I-MSH2 1.03 0.62- 1.70 0.85 0.50- 1.44
%-MSH2 1.67 1.02 - 2.73 1.36 0.80-2.32
I-p53 0.97 0.71 - 1.32 0.90 0.66- 1.23
%-p53 1.03 0.77- 1.40 0.92 0.66-1.27




1.39 0.76-2.55 2.37 1.18-4.76
p=0.016
*Multiplicative change in hazard for a unit increase in the corresponding variable
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E - CORRELATION OF IMMUNOSCORES WITH RESPONSE (tumour
shrinkage) TO CHEMOTHERAPY
Of the 58 patients, 22 had no evaluable disease or did not have repeat assessments. 7
patients had stable disease or progressive disease (19%) while the remaining 29 had a
response (CR or PR=81%). To investigate whether clinical factors or MMR, p53 or
Ki67 immunohistochemistry predicted for response we used a logistic regression
model. Response (CR or PR) was compared to no response (SD or PD) and was again
stratified for the type of chemotherapy given. Immunoscores and clinical factors were
examined individually and then the immunoscores were examined in a model
containing 3 prognostic factors. The results are shown in table 40.
There was no significant correlation of response with stage, performance status, or
residual disease. Of all of the immunoscores only the p53 %-score suggested any
association with response (multivariate analysis HR=2.89; 95%CI=0.86-9.73;
p=0.059). This suggests that tumours with an increased percentage of cells expressing
p53 showed a trend towards a better response to treatment, shown in figure 18. On
this occasion loss of I-MMR (i.e. I-MLH1 <=1.5 and/or I-MSH2 <= 1.5) showed no
association with response on univariate or multivariate analysis.
Another surrogate measurement of response to chemotherapy in ovarian cancer is the
rise or fall of the tumour marker CA 125 during treatment. Unfortunately there were
insufficient measurements in these patients to permit this to be analysed.
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Table 40 - Results of logistic regression for association with response
Univariate Multivariate










I-MLH1 1.73 1.93 0.36-10.40
%-MLHl 0.89 0.99 0.19-5.10
I-MSH2 0.98 0.92 0.20-4.16
%-MSH2 0.58 0.61 0.11 -3.43
I-p53 1.46 1.62 0.61-4.35
%-p53 2.40 2.89 0.86-9.73





*Multiplicative change in odds in favour of response for a unit increase in the
corresponding variable. Significant values shown in bold.
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F - CONCLUSIONS OF CORRELATION OF IMMUNOSCORES WITH
CLINICAL FEATURES AND OUTCOME
• Advanced stage (stage III/IV) is correlated with increasing expression of MLH1,
MSH2 and Ki67. As stage itself is a known prognostic factor any prognostic
study ofMMR proteins will need to correct for stage.
• There was no association ofMLH1, MSH2, Ki67 or p53 with residual disease or
performance status.
• There was an association of lower expression of MMR proteins in
adenocarcinoma histological subtype.
• Loss of mismatch repair, as defined by an intensity score below the mid-range
value of 1.5 for either MLH1 or MSH2, was shown to predict for poor overall
survival and decreased time to progression on multivariate analysis. This is
clinical evidence supportive of the in-vivo and in-vitro data discussed in the
introduction suggesting that loss of MMR is important in resistance to platinum
based chemotherapy.
• On multivariate analysis for survival reduced intensity of MLH1 staining was
found to be statistically significantly associated with poorer overall survival. This
suggests that prechemotherapy MLH1 protein expression is associated with
clinical outcome in this group of ovarian cancer patients treated with platinum
based chemotherapy.
• As expected advanced stage and residual disease >2cm were associated with poor
overall survival and reduced time to progression.
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• On univariate analysis increasing %-MSH2 score was significantly associated
with poor overall survival and reduced time to progression but this was due to its
association with advanced stage and lost significance on multivariate analysis.
This supports the need to have clinical prognostic factors accounted for in any
study such as this.
• There was no statistically significant association of any immunostain with
response to chemotherapy but the numbers included were small in keeping with
the difficulty of obtaining accurate response data in ovarian cancer patients.
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G - MULTIPLE IMMUNOSCORES FOR THE SAME PATIENT
A - PAIRED PREAND POST CHEMOTHERAPYSAMPLES
Paired blocks of tissue were obtained from 26 patients taken at the initial diagnostic
laporotomy prior to chemotherapy and at a second operation following chemotherapy.
The patient characteristics are shown in table 41. There was an excess of patients
with more advanced stage compared to the patient characteristics for
prechemotherapy samples (n=58) but no other significant differences. Patients with
advanced disease are more likely to have residual disease and, therefore, a second
operation. The timing of the second operation varied. 18 of the 26 patients had repeat
operations within 12 months of their initial laporotomy {postchemotherapy residual
paired samples). 12 of the 26 patients had repeat operations at least 12 months after
their initial laporotomy (relapsed paired samples). Four of the 26 patients had
multiple operations both within and after a 12 month period following diagnosis. The
numbers of paired samples are small and therefore any conclusions are limited due to
sample size.
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Table 41 - Patient characteristics for paired samples
(N=26) N= %
Chemotherapy Cisplatin (5 (^/Cyclophosphamide 10 38
Cisplatin (100)/Cyclophosphamide 8 31
Cisplatin (100)/Cyclophosphamide 3 11
Cisplatin (75)/ Taxol 2 8
Cisplatin (75)/ Cyclophosphamide 3 11




Performance Status 0 8 31
1 15 58
2 3 11
Residual Disease <2cm (1) 8 31
2cm or greater (2) 18 69
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A (I) - Difference in paired sample scores (n=26)
There was no significant difference found between pre and post chemotherapy
immunoscores, (using Wilcoxon matched pairs signed ranks test), as shown in table
42.





















I-MSH2 2.08 1.99 11 11 4 0.51
%-MSH2 2.44 2.38 10 13 3 0.39
I-p53 2.20 2.07 5 10 11 0.47
%-p53 2.33 2.25 8 8 10 0.90
I-MLH1 1.96 1.81 10 15 1 0.35
%-MLHl 2.35 2.27 8 10 8 0.78
%-Ki67 17.91 16.62 8 15 1 0.41
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A (II) - Correlation ofchange in immunoscore postchemotherapy with survival
To determine whether altered expression of either MMR proteins, p53 or Ki67
following cisplatin containing chemotherapy had an impact on survival, a Cox
univariate and multivariate analysis was performed using the difference in score (pre-
post chemotherapy immunscores). The multivariate analysis included the known
clinical prognostic variables of initial performance status, residual disease and stage.
Data was censored for one case that progressed early and the analyses were stratified
for chemotherapy regimen (i.e. cisplatin dose). The median overall survival for these
patients was 34 months. The results are shown in table 43. No significant difference
was found suggesting that the change in MMR. p53 or Ki67 protein expression after
chemotherapy, as measured by immunohistochemistry, does not predict for overall
survival in these patients.
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Table 43 - Results of univariate and multivariate analyses for survival with difference








I-MSH2 0.70 0.40-1.24 0.65 0.35-1.19
%-MSH2 1.13 0.70-1.84 1.25 0.73-2.13
%-Ki67 1.00 0.96-1.05 1.00 0.95-1.05
I-p53 1.06 0.60-1.85 1.10 0.61-1.98
%-p53 0.84 0.52-1.34 0.79 0.48-1.32
I-MLH1 0.82 0.39-1.74 0.79 0.27-2.32
%-MLHl 1.02 0.58-1.78 0.81 0.33-1.99
Residual Disease 0.97 0.31-3.06
Stage 1.02 0.27-3.92
Performance Status 1.32 0.43-4.04
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A (III) - Correlation of change in immunoscore yostchemotherapy with time to
progression (TTP)
Similarly, to investigate whether altered expression of either MMR proteins, p53 or
Ki67 following cisplatin containing chemotherapy had an impact on time to
progression a Cox univariate and multivariate analysis was performed using the
difference in score (pre-post chemotherapy) and the known clinical prognostic
variables of initial performance status, residual disease and stage. Data was censored
for one case that progressed early and the analyses were stratified for chemotherapy
regimen. The median time to progression for these patients was 19 months. The
results are shown in table 44.
On both univariate and multivariate analysis there was a significant association found
with the change in intensity score for MSH2 (I-MSH2) and TTP. The likelihood ratio
p values were 0.035 for the univariate and 0.011 for the multivariate analyses. 11
patients showed an increase in I-MSH2 score after chemotherapy with a median TTP
of 361 days. 15 patients showed a reduced or stable I-MSH2 score following
chemotherapy with a longer median TTP of 834 days. This suggests that a loss of
MSH2 expression after chemotherapy with a cisplatin containing regimen is
associated with a prolonged time to progression. This is shown on the Kaplan Meier
curve in figure 19.
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Table 44 - Results of univariate and multivariate analyses for time to progression with










I-MSH2 0.59 0.35-0.997 0.52 0.30-0.90
%-MSH2 1.2 0.79-1.83 1.37 0.88-2.12
%-Ki67 0.998 0.96-1.03 0.99 0.95-1.03
I-p53 0.99 0.60-1.62 1.04 0.63-1.72
%-p53 0.92 0.60-1.41 0.88 0.56-1.36
I-MLH1 0.68 0.35-1.34 0.60 0.23-1.56
%-MLHl 1.10 0.65-1.85 0.90 0.42-1.94
Residual Disease 0.93 0.35-2.46
Stage 1.14 0.31-4.24
Performance Status 1.55 0.53-4.49
Significant values shown in bold.
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Figure 19 - Kaplan-Meier curve for time to progression stratified for increase or
decrease in I-MSH2 score postchemotherapy (n=26)
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This shows that patients with a loss of intensity ofMSH2 staining post chemotherapy
have a longer time before their ovarian cancer shows progressive disease.
A (III) - Conclusions from paired samples
There is no consistent difference in immunoscores pre and post chemotherapy.
However, patients with a loss of I-MSH2 staining post chemotherapy show a
significantly longer TTP (p=0.011 on multivariate analysis). However the number of
patients examined with paired samples is small, and includes both residual and
relapsed pairs. Any firm conclusions are therefore very limited.
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B - IMMUNOSCORES FROMMULTIPLE OPERATIONS
Multiple blocks were obtained from 5 patients who had more than 2 operations for
ovarian cancer. In one of these no pre-chemotherapy block was obtained. No clear
pattern for change over time with either MMR, p53 or ki67 expression was observed
in this very small number of patients. Results are shown in bar charts in figure 20
below.
Figure 20 - Bar charts of change in immunoscores with multiple operations
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H - ADDITIVE HISTOSCORE
In view of the wealth of literature on combined histoscores (see introduction) we
investigated whether an additive Histoscore (H) calculated by; Intensity score (0 to 3)
+ Percentage score (0 to 3) for MLH1, MSH2 and p53 would provide any additional
prognostic information (i.e. from 0 to maximum 6). On univariate and multivariate
Cox analysis for survival and progression free survival there were no new significant
results and indeed the significant results for I-MLH1 on multivariate analysis for
survival were lost, shown in table 45.








H-MLH1 0.93 0.68-1.26 0.74 0.52-1.05
H-MSH2 1.09 0.82-1.43 0.93 0.69-1.25
H-p53 0.96 0.80-1.14 0.88 0.74-1.06
Progression
Free Survival
H-MLH1 0.99 0.75-1.31 0.85 0.62-1.16
H-MSH2 1.12 0.86-1.45 1.00 0.76-1.33
H-p53 1.00 0.86-1.17 0.95 0.81 - 1.12
*Multiplicative change in hazard for a unit increase in the corresponding variable
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Likewise for correlation with histology the additive histoscore loses any significance
for MSH2 and are less significant for H-MLH1 compared to %-MLHl alone (p=0.015
and 0.0076 respectively), shown in table 46.
Table 46 - Results of additive histoscore and histology




18 20.74 28.29 27.06
Adenocarcinoma 16 19.73 18.46 23
Papillary
adenocarcinoma
20 32.42 26.53 24.53
Chi-Square (2df) 8.45 3.89 0.66
P= 0.015 0.14 0.72
By logistic regression none of the H-scores showed a significant association with
response to chemotherapy which is identical to the results for I-scores and %-scores
alone, shown in table 47.
Table 47 - Results of additive histoscore with response
Correlation with response H-MLH1 H-MSH2 H-p53
p value 0.77 0.72 0.20
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The only histoscore that has shown an increased sensitivity compared with %-score or
I-score alone is that for the correlation of MSH2 with stage. Both I-MSH2 and %-
MSH2 show a correlation with stage (p=0.019 and 0.0049 respectively) and the
additive histoscore is more significant than either alone (p=0.0034). This does not
hold true for MLH1, shown in table 48.
Table 48 - Results of additive histoscore with clinical factors






H-MLH1 0.029 0.94 0.99
I-MLH1 0.062 0.86 0.97
%-MLHl 0.0092 0.86 0.77
H-MSH2 0.0034 0.12 0.8
I-MSH2 0.019 0.19 0.89
%-MSH2 0.0049 0.23 0.4
H-p53 0.36 0.95 0.51
Examination of the Spearman rank correlation coefficients between histoscores shows
no added sensitivity for H-scores compared to I-scores or %-scores, shown in table
36. In particular the significant correlation of H-MLH1 with H-MSH2 (r=0.27;
p=0.042) is no greater than the correlation of %-MLHl and %-MSH2 (r=0.30;
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p=0.022). Similarly, the correlation of %-Ki67 with H-MLH1 and H-MSH-2 (r=0.44;
p=0.001 and r=0.34; p=0.009 respectively) is no better than that with %-MLHl and
%-MSH2 (r=0.46; p<0.001 and r=0.44; p=0.001 respectively).
Conclusions for use ofadditive histoscore
Apart from the single correlation of stage and H-MSH2 additive score there is no
evidence to support the use of an additive histoscore instead of separate Intensity and
Percentage score in these three antibodies.
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Table 49 - Results of correlation of additive histoscores
H-MSH2 H-p53 H-MLH1
Ki67 0.34; 0.066; 0.44;
0.009 0.63 0.001
H-MSH2 NA 0.016; 0.27;
0.90 0.042
I-MSH2 NA 0.062; 0.22;
0.64 0.10
%-MSH2 NA -0.051; 0.23;
0.70 0.077
H-p53 0.016; NA 0.15;
0.90 0.25
I-p53 0.0005; NA 0.12;
0.997 0.35
%-p53 0.019; NA 0.17;
0.89 0.21
H-MLH1 0.27; 0.15; NA
0.042 0.25
I-MLH1 0.25; 0.21; NA
0.062 0.12
%-MLHl 0.29; 0.11; NA
0.03 0.42
• Spearmank Rank correlation coefficients (r) shown above
• p values shown below in italics
• Significant (p<0.05) values shown in bold






Endometrial carcinoma is the most common non-colorectal carcinoma in women
affected by HNPCC, and microsatellite instability has been observed both in the
inherited form and in approximately 20% of presumed sporadic endometrial
carcinomas (Risinger, Berchuck et al. 1993; Burks, Kessis et al. 1994). The aim of
this small study was to examine the expression of hMLHl and hMSH2, compared to
p53 and Ki67 in the normal stages of endometrial development, atypical endometrium
and endometrial carcinoma.
B - MATERIALS AND METHODS
The immunohistochemistry for the four antibodies was performed as previously
described in methods chapter. Scoring was done by only one observer (DM) due to
the difficulty in interpretation of pathology of endometrial tissues. On this occasion
scoring for Ki67 was performed as per MMR and p53 on a scale of 0 to 3 for both
intensity and percentage. Each antibody was run independently on two separate slides
for each case and each slide scored blindly on separate occasions. The final scores are
a mean of the two results. Five different patients' slides were used to examine the
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range of expression of MMR proteins from normal to carcinoma. These slides were
of normal proliferative endometrium, normal early secretory, normal late secretory,
hyperplastic endometrium and endometrial carcinoma.
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C - RESULTS
As only 10 slides were examined in total no attempt has been made to examine
statistical significance in this small sample.
Immunoscores are shown in table 50 and figure 21 below. Proliferation was high in
all phases of endometrial tissue examined apart from the late secretory phase. This is
the normal phase of specialisation of the endometrial tissue. By contrast MMR
proteins hMLHl and hMSH2 both showed a fall in expression in both the early and
late secretory phase of differentiation. In the abnormal hyperplastic endometrium
hMLHl was increasingly expressed, unlike hMSH2 and p53. With the frankly
carcinomatous endometrium both MMR proteins were strongly expressed. P53 was
also overexpressed suggesting that the mutant form were present.
Figure 21 - Additive histoscores of immunohistochemistry in endometrial samples






proliferative early secretory late secretory hyperplastic carcinoma
Type of endometrium
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Table 50 - Results of immunohistochemistry scores of endometrial samples (n=5)
Type of
endometrium
Proliferative Early secretory Late secretory Hyperplastic Carcinoma
I-MLH1 1.67 0 0.33 1 1.5
%-MLH1 2 0 0 1.67 2
H-MLH1 3.67 0 0.33 2.67 3.5
I-MSH2 2 0 0.75 0.5 3
%-MSH2 1.75 0 0.25 0.5 3
H-MSH2 3.75 0 1 1 6
l-p53 1 0.5 0 0 1
%-p53 1.5 0.5 0 0 1.5
H-p53 2.5 1 0 0 2.5
I-Ki67 3 3 0 3 3
%-Ki67 2 2 0 2 2
H-Ki67 5 5 0 5 5
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D - DISCUSSION
This small study suggests that up regulation of MMR proteins occurs in malignant
compared to normal differentiated secretory endometrium. This is in keeping with a
much larger study comparing hMSH2 expression in malignant (n=40) and secretory
normal endometrium (n=15) (Freidrich, Villena-Heinsen et al. 1999). They found
hMSH2 was consistently and strongly up regulated in endometrial carcinoma
compared to normal endometrium in the secretory phase (p<0.001). Interestingly they
showed no association of hMSH2 staining with Ki67 staining.
It has been shown that MSI in sporadic endometrial carcinomas is not due to
mutations in hMSH2, hMLHl, hPMSl or hPMS2 (Katabuchi, van Rees et al. 1995;
Lim, Tester et al. 1996). The MSI may be due to hypermethylation of the promoter
silencing the MMR gene. In 14 MSI endometrial carcinomas no gene defects in
MLH1 or MSH2 were detected but hypermethylation of the MLH1 promoter regions
was identified in 10 case (71%) (Gurin, Federici et al. 1999). Flowever,
immunohistochemistry for hMLHl and hMSH2 is intact in MSI positive endometrial
tumours (Lim, Tester et al. 1996) suggesting that there is some expression ofMLH1.
It may be hMSH3 or hMSH6 that is important in these tumours to account for the
MSI phenotype. It has been shown that patients with more advanced endometrial
cancer (Stage III or IV or with lymph node metastases) are more likely to have MSI.
Also no MSI was found in 26 patients with precancerous atypical endometrial
hyperplasia (Ohwada, Suzuki et al. 1999). This suggests that MSI is a late finding in
endometrial carcinoma.
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Chapter 9 - DISCUSSION
1. PRINCIPAL FINDINGS
a) Key clinical finding
We have shown that reduced expression of the DNA mismatch repair genes MLH1
and/or MSH2, by intensity of immunohistochemistry, in pre-chemotherapy samples
from patients with ovarian cancer who are subsequently treated with cisplatin
containing chemotherapy, independently predicts for poor progression free and
overall survival.
b) Other Clinical Findings in ovarian cancer patients
• Reduced expression of MLH1 prechemotherapy independently predicts for poor
overall survival.
• Ki67 and p53 expression does not predict outcome in this group of ovarian cancer
patients.
• Advanced stage of tumour is associated with an increased percentage of cells
expressing Ki67, MSH2 and MLH1 and increased intensity ofMSH2. There is no
correlation with immunoscores and residual disease or performance status.
• Reduced expression of MMR proteins is seen in the adenocarcinoma histological
subtype.
• There was no significant difference found in pre and post chemotherapy
expression ofMLH1, MSH2, p53 or Ki67 in our group of patients.
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• An increase in expression of MSH2 post chemotherapy independently predicts for
poor progression free survival but not overall survival.
c) Technical Findings
• It is possible to immunostain paraffin embedded tissues for MMR proteins, MLH1
and MSH2 in a consistent manner.
• Using a four-point scale for both intensity and percentage of cells stained it is
possible to obtain good correlation in inter-observer, intra-observer and intra-slide
scores.
• The intensity of staining is closely correlated to the percentage of cells stained.
• Immunostaining for MLH1 and MSH2 are correlated with each other and increase
with increasing proliferation as measured by Ki67.
• MMR immunostaining is not correlated with p53 immunostaining.
• There was no advantage of an additive histoscore (I+%) and the correlation of
MMR and survival was lost.
2. STENGTHS AND WEAKNESSES OF THIS STUDY
In an editorial on statistical issues in cancer research Simon and Altman describe the
key features of a study on prognostic factors for valid conclusions to be drawn (Simon
and Altman 1994). These are the first set of guidelines for such studies and provide a
framework to assess the results of different prognostic factor studies that are often
inconsistent or contradictory. Using these 11 guidelines the current study has been
examined for possible strengths and weaknesses.
1. Intra- and inter-laboratory reproducibility ofassays should be documented.
Intra-laboratory reproducibility of the immunostaining was provided by staining 2
slides for each case, on separate occasions (the intra-slide variability). The kappa
scores ranged from 0.583 for intensity of MLH1 to 0.905 for intensity of p53. For
immunohistochemistry it is also important to state the inter- and intra-observer
variability for the scoring system used. We found this to have a kappa score
consistently above 0.6 for all antibodies. The inter-laboratory reproducibility of the
staining has not been tested. The use of both positive and negative control slides in
each run developed for this study e.g. A2780 +ve and CP70 -ve for MLH1 should
help in quality assurance between laboratories.
2. Laboratory assays shoidd be performed blinded to clinical outcome.
The 2 scorers for the immunohistochemistry were both blinded to clinical outcome
and to each other's results.
3. A clear inception cohort ofpatients should be assembled with few (e.g.<15%)
patients non-evaluable due to missing material or data. The referral pattern and
eligibility criteria should be described so that generalisability of results can be
evaluated.
The study was potentially subject to selection bias as patients were chosen on the
availability of histological material, although all patient samples that could be
retrieved were included. Patients entered into the 3 trials included came from the
entire West of Scotland region and 12 different pathology laboratories were involved
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in retrieving blocks for the current study. Comparing the patient characterisits in
our study (n=58) to those in the study by Kaye et al. (n=159) (Kaye, Paul et al. 1996)
we found no difference in the stage, presence of residual disease or performance
status between the two cohorts (by X2 analysis; p>0.05; data not shown) suggesting
that our group of patients was representative.
4. Treatment (or absence of treatment) should be standardised or randomised and
accountedfor in the analysis and interpretation.
Patients received 4 different chemotherapy regimens within 3 separate trials. We
stratified the Cox analyses for chemotherapy to remove the effect of regimen,
including dose of cisplatin, from the analysis. All patients were managed by the
same multidisciplinary team after initial diagnosis. Any future studies should be on a
larger group of patients all treated with the same protocol for surgery (both initially
and after chemotherapy) and chemotherapy regimen. However, prospective validation
studies in ovarian cancer may be complicated by the inclusion of taxanes in treatment
protocols, since taxanes are believed to induce cytotoxicity in a manner independent
ofMMR status (Fink, Aebi et al. 1998).
5. Hypotheses to be tested should be stated in advance. The hypotheses should
include specification ofendpoints, cut-offvalues for prognostic variables, subsets
ofpatients, treatment, standard prognostic factors or classifications to be used
that are relevant to the hypothesis.
The hypothesis that loss of MMR proteins, in particular MLH1, may lead to cisplatin
resistance and therefore poor outcome in ovarian cancer patients was stated in the
aims of this thesis which were submitted to University of Edinburgh in advance as
part of the MD application. The end points of overall survival, progression free
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survival and response were also stated. The immunoscores individually were
examined as continuous variables and therefore cut-off points were not used.
However, the cut-off point for loss of intensity ofMMR staining (i.e. I-MLH1<=1.5
and/or I-MSH2<=1.5) was not stated in advance and can therefore be criticised.
6. The number ofpatients and number of 'events' should be sufficiently large that
statistically reliable results are obtainable. Statistical power calculations that
incorporate the number ofhypotheses to be tested and the appropriated subset of
patients (e.g. node-negative) for each hypotheses should be described.
In keeping with many prognostic studies we are guilty of not stating the statistical
power and number of patients required in advance of the study. There were no patient
subset analyses performed on this group of patients. The sample size calculations
become particularly important when considering 'negative' results that may be merely
'uninformative' due to small sample size. The positive results from our study are thus
less of a concern. The observation in the present study that loss ofMMR predicts for
progression-free and overall survival, but not for response is perhaps surprising,
although defining response in ovarian cancer is fraught with difficulties. The number
of patients that could be assessed for response was small, with only 7 patients having
stable or progressive disease and thus limiting the power of the statistical analysis.
7. Analyses should test whether new assays add predictiveness once outcome is
adjustedfor the effect ofstandardprognostic factors.
We were very careful in this study to include known prognostic variables for ovarian
cancer in a multivariate analysis. The only variables we did not adjust for were
histology and FIGO grade of tumour both of which have not been shown to be a
consistent prognostic variable.
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8. The analyses should be adjustedfor the number ofhypotheses to be tested.
Although the present study was designed to specifically examine the prognostic value
of MLH1 and MSH2, there is a danger that examination of multiple parameters can
lead to a statistical correlation by chance. Clearly the current study needs independent
validation. Indeed a significant value should only be accepted if the computed p-
valued is less that 0.05 x C, where C = the number of comparisons. In our study there
were 8 variables tested (I-MLH1, %-MLHl, I-p53, %-p53, I-MSH2, %-MSH2, %-
Ki67 and Loss of I-MMR) against outcome. The finding that loss of MMR is
associated with poor overall survival survives this scrutiny with a p value of (0.0012 x
8) = 0.0096. However the significance of loss ofMMR with progression free survival
and I-MLH1 with overall survival is lost.
9. Analyses shoidd be based on prespecified cut-off values for prognostic variables
or cut-offs should be avoided.
We have analysed individual immunoscores as continuous variables with no cut-off.
The use of cut-off for loss of I-MMR was based entirely on this being the middle of
the range of scores, but can be criticised as a cut-off.
10. Confidence intervals should be provided to indicate the uncertainty in estimates.
The 95% confidence intervals for the hazard ratios are stated for the multivariate
analyses.
11. Claims ofsubset-specific treatment effects should be documented by a test of the
single global null hypothesis that there is no treatment specificity involving any of
the subsetting variables.
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We have not used any subsets of patients in our analyses.
Criticisms of the immunoscoring technique.
We have used a semi-quantitative method to look at both intensity and percentage of
cells showing positive immunostain. We found the score for intensity of staining of
MLH1 to be of more prognostic value than the score for percentage of cells stained.
This may have been due to the limited number of categories in the percentage scoring
system used. The correlation of the immunostain score with MSI or protein
expression by Western analysis has not been studied in this group, but in a previous
study in 297 colorectal tumours there was a 100% specificity and 100% sensitivity of
immunostaining to predict MSI (Cawkwell, Gray et al. 1999). Summarising all the
available studies we found immunohistochemical analysis to have a 98.9% power to
predict MSI. The studies for immunohistochemistry to predict MMR gene mutation
are much more limited but we found a positive predictive power of 76%. It is not
known what level of expression of MMR proteins is required to affect
immunostaining, to produce MSI or to affect drug sensitivity. Interestingly it has
been shown in a melanoma cell line that resistance to cisplatin, etoposide and
vindesine is associated with reduction in MMR proteins; MLH1, MSH2 and MSH6 as
shown by Western blot analysis, but does not give rise to the MSI phenotype (Lage,
Christmann et al. 1999). In this model a reduction in MMR rather than complete loss
was associated with chemotherapy resistance. More work on the relevance of
immunostaining to predict functionally important loss ofMMR is required.
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3. RELATION TO OTHER STUDIES
In vitro it has been shown that ovarian tumour cell lines, which have acquired
cisplatin resistance, also frequently show loss of MLH1 compared to parental cell
lines (Aebi, Kurdi-Haidar et al. 1996; Brown, Hirst et al. 1997). A recent study of 54
ovarian cancer patients treated with platinum based chemotherapy, did not show an
association of prechemotherapy MLH1 or MSH2 immunohistochemical staining with
overall survival (Samimi, Fink et al. 2000). There are differences between this
previous study and the present one in terms of the patient populations, chemotherapy
regimens and immunohistochemistry scoring, and there are also differences in how
the data have been analysed. In the Samimi study all patients were FIGO stage 3 or 4
whereas 26% of the patients in our study were stage IC or II. Their patients were
selected from studies involving second look laparotomy after at least 2 cycles of
chemotherapy, which suggests, (although not stated), that the majority of patients had
residual disease after their initial laparotomy. By contrast one third of our patients
had minimal residual disease. Both of the above suggest that their population was of
a more advanced, and therefore poorer prognostic stage. Their patient population
received either cisplatin or carboplatin (doses not stated) based chemotherapy as first
line treatment. It is unknown if any of the patients also received taxoids. Our results
were stratified for cisplatin regimen, to avoid any bias from dose of chemotherapy,
which has been shown to be important for survival (Kaye, Paul et al. 1996). For
immunohistochemical scoring they used a single scorer, blinded to clinical outcome.
They used an intensity scale from 0-4 compared to our study of 0-3. For percentage
of cells they used decades (0-100% in 10% increments) compared to our 0-3 scale.
This more extensive scale may have lent itself to more accurate interpretation but
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unfortunately no assessment of variability of scoring such as a kappa scoring was
included, and inter-observer variability was not examined.
On analysis they confirm our finding that intensity and percentage staining for MMR
proteins are closely correlated. This suggests the two staining characteristics are not
independent of each other. They also confirm that hMLHl staining is positively
correlated with hMSH2 staining, suggesting there is coordinated regulation of MMR
protein expression in ovarian cancer.
Of contrast, in particular, the present study has identified a significant association
with survival using multivariate analysis of the combined MLH1 and MSH2
immunoscores. Loss of either MLH1 or MSH2 can lead to loss of MMR. We have
also shown that loss of MLH1 is associated with poor overall survival only on
multivariate analysis. The previous study used only univariate analysis of the
individual proteins (Samimi, Fink et al. 2000). Multivariate analysis is necessary to
uncover any significant associations that may be masked by other clinical features that
affect response to chemotherapy. Thus, we have shown a correlation of a low score
for MLH1 with early stage (i.e. IC or II), which is, by itself, a good prognostic factor.
The correlation of MMR deficiency and early stage was noted in a previous study of
microsatellite instability in ovarian neoplasms (King, Carcangiu et al. 1995) with 75%
of stage I patients showing MSI compared to 11% of stage II, III or IV tumours
(p=0.01). Because of this association of loss ofMMR with stage, if only a univariate
analysis of MMR expression was considered any correlation of MMR with survival
may be obscured. Indeed on univariate analysis we do not observe an association with
survival. It is only on correcting for clinical prognostic factors by multivariate
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analysis that the true poor prognostic association with loss of MMR expression is
revealed.
Although the patients in the Samimi study were all of an advanced stage, they have
not analysed survival corrected for histology, grade of tumour, residual disease,
performance status or chemotherapy regimen, all of which may influence survival.
They did not show any association ofMMR protein staining with FIGO grade or age.
They did show an association of lower intensity of MSFI2 staining pretreatment in
stage 4 compared to stage 3 patients (p=0.0236). We did not examine the difference
between stage 3 and 4 patients but, by contrast, found a loss of MMR staining with
stage IC or II compared to stage 3 or 4. They confirmed our finding that patients with
serous adenocarcinoma tended to have a higher expression of MMR proteins.
However, they did not include the 'not otherwise specified' subtype histology in their
analysis, which comprised 33% of their patients. We found that adenocarcinoma
(poorly differentiated) showed a lower expression ofMMR proteins. In concordance
with our study they found no relationship between pretreatment MLH1 or MSH2
staining and response to chemotherapy.
An increase in the proportion of ovarian tumours negative for MLH1 in samples from
patients taken after platinum-based chemotherapy compared to untreated tumours has
been previously shown (Brown, Hirst et al. 1997; Fink, Nebel et al. 1998; Samimi,
Fink et al. 2000). In our study we saw no significant change in pre and post
chemotherapy staining for MLH1 or MSH2. However, in a similar clinical study
Samimi et al. (Samimi, Fink et al. 2000) showed a mean reduction of 15% for MSH2
and 18.7% for MLH1. It is clearly possible that we lost the sensitivity to detect such a
change by our 0-3 scale for percentage staining. In particular, any changes between
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20 and 80% would have all fallen into category 2. Interestingly, their study showed
no difference in change ofMMR proteins regardless of whether the biopsy was within
4 months or 10 months after chemotherapy. They showed no correlation of change in
MMR staining with chemotherapy and survival in keeping with our study. In
contrast, loss of MLH1 staining, shown in post chemotherapy samples from breast
cancer patients receiving neoadjuvant chemotherapy, was a predictor for poor disease
free survival (Mackay, Cameron et al. 2000). Counterintuitively, in the Samimi study
loss of intensity or percentage of MLH1 staining in the post chemotherapy samples
was found to be associated with a good response to treatment (p=0.0081 and 0.0178
respectively). However, this result was not subject to a multivariate analysis for other
predictors of chemotherapy response. In our study we found a similar contrary result
that a reduction in intensity ofMSH2 staining post chemotherapy was associated with
a good progression free survival on multivariate analysis. These results cannot be
easily explained. It is difficult to know what residual tumour represents at second
look laparotomy in ovarian cancer patients, especially as early as after 2 cycles of
chemotherapy as in the Samimi study. Some residual tumour may represent resistant
disease whereas other tumour may represent responding, but not yet completely
responding, tumour.
In ovarian cancer patients a correlation between positive p53 immunohistochemistry
or p53 mutations of tumours and poor response to cisplatin/carboplatin based
chemotherapy has been shown (Righetti, Torre et al. 1996), although studies on p53
status and overall survival have been conflicting (see table 18). Consistent with some
studies, p53 immunostaining showed no significant independent prognostic value in
our study (Hartmann, Podratz et al. 1994; Sheridan, Silcocks et al. 1994; van der Zee,
Hollema et al. 1995; Goff, Muntz et al. 1998; Marx, Meden et al. 1998) and was
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independent of expression of either MLH1 or MSH2 or Ki67. Immunohistochemical
detection of p53 does not necessarily indicate expression of a mutated protein, but it
may be a useful marker for the presence of a functionally abnormal p53 protein
(Wynford-Thomas 1992; Hall and Lane 1994). The difference in these results may be
due to the use of different antibodies and antigen retrieval techniques (Lambkin,
Mothersill et al. 1994; Baas, van den Berg et al. 1996) or due to difference in scoring
of immunostaining (Geisler, Geisler et al. 1997). The only previous study using the
same antibody as in the current study (Ab-6) used a cut-off point of over 20% cells
staining as positive, whereas we treated both the intensity and percentage scores as
continuous variables (Rohlke, Milde-Langosch et al. 1997). They also used overnight
incubation as opposed to our microwave antigen retrieval. In 104 ovarian cancer
patients they found an association of 'positive' p53 staining and poor overall survival
on multivariate analysis (p=0.014). In their multivariate analysis they included
histological grade but not performance status or residual disease as important clinical
prognostic factors. Our study may have been limited due to number of patients.
Following the observation on light microscopy of differential expression of MMR
genes in normal tissue with a tendency to increased expression in the proliferating
compartments e.g. crypts of Lieberkuhn, we felt it was important to stain the material
for Ki67 as a surrogate marker for proliferation (Wilson, Ewel et al. 1995; Leach,
Polyak et al. 1996). Our finding of a positive correlation of increasing MLH1 and
MSH2 scores with increasing Ki67 scores lend support to this observation. Six
studies have shown increased Ki67 expression in ovarian cancer to be associated with
poor overall survival on univariate analysis (Jordan, Kerns et al. 1993; Kerns, Jordan
et al. 1994; Altavilla, Marchetti et al. 1996; Layfteld, Saria et al. 1997; Anttila, Kosma
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et al. 1998; Goff, Muntz et al. 1998). However, the association of increased Ki67
expression with advanced stage, (a poor prognostic indicator), as found in the current
study, is confirmed by Altavilla et al. (Altavilla, Marchetti et al. 1996). Only one
study performed a multivariate analysis including stage (Anttila, Kosma et al. 1998).
It showed an independent association of increased Ki67 expression and overall
survival but the p value was marginal (p=0.04). Our study did not support Ki67 as an
independent prognostic indicator in keeping with a previous study by Rohlke et
al.(Rohlke, Milde-Langosch et al. 1997).
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4. MEANING OF STUDY AND POSSIBLE MECHANISMS
How mismatch repair deficiency could lead to the development of drug resistance is
not yet fully understood. The mismatch repair protein MutSa (a heterodimer of
MSH2 and MSH6) recognizes and binds to sites of DNA damage such as 06meG and
1,2 cisplatin intrastrand crosslinks (Duckett, Drummond et al. 1996; Yamada,
O'Regan et al. 1997). This has been suggested to lead to either futile rounds of DNA
repair (Karran and Hampson 1996), replication stalling (Brown, Hirst et al. 1997), or
reduced replication bypass (Vaisman, Varchenko et al. 1998; Durant, Morris et al.
1999) causing increased activation of an apoptotic pathway. An alternative
explanation for the correlation of loss of MMR with drug resistance is that loss of
MMR leads to a mutator phenotype and therefore may be a surrogate marker for other
changes leading to a more aggressive tumour. However, restoration of MMR by
chromosome transfer in deficient cells restores drug sensitivity including to cisplatin,
arguing for a direct role for MMR in determining cell death and chemosensitivity
(Aebi, Kurdi-Haidar et al. 1996; Fink, Nebel et al. 1996). More recently restoration of
the MLH1 gene itself into MLH1 deficient strain of Saccharomyces cerevisiae has
been shown to increase sensitivity to cisplatin compared to vector alone control
(Durant, Morris et al. 1999).
The control of expression of MMR genes is as yet poorly understood. Recent
observations have shown that the promoter of the MLH1 gene undergoes
hypermethylation in ovarian, colorectal and gastric tumours as well as cisplatin
resistant cell lines and that this correlates with loss ofMLH1 expression (Kane, Loda
et al. 1997; Leung, Yuen et al. 1999; Strathdee, Mackean et al. 1999). It is of note
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that cisplatin itself can cause hypermethylation of such CpG rich promoter regions
(Nyce 1989). This may explain why MLH1, out of all of the MMR proteins, is
frequently lost in chemotherapy resistant models.
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5. UNANSWERED QUESTIONS AND FUTURE RESEARCH
Our study demonstrates the potential clinical prognostic value of loss of MLH1 and
MSH2, as shown by immunohistochemistry, in pre-chemotherapy samples from
ovarian cancer patients. Prospective, independent studies are required to confirm this
finding and are ongoing. If the association of loss of MMR and poor survival and
resistance is confirmed, future treatment strategies could specifically address the issue
of targeting cells with loss ofMMR or could involve the development of agents which
are active in MMR deficient tumour cells e.g. taxoids, topo I - isomerase inhibitors or
oxaliplatin.
A larger study is needed to examine the clinical significance of reduction in MLH1
after chemotherapy. Particular care should be taken to examining why the second
laparotomy has been performed. The use of decades instead of a 4 point scale for
percentage of cells positive for MMR proteins should be explored, including inter-
observer and intra-observer variation.
Work with serum DNA in ovarian cancer patients is ongoing. It remains to be
established whether this does indeed represent tumour DNA. The clinical usefulness
of this, e.g. to predict overall survival or response to chemotherapy, then needs to be
explored.
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